WO2021001244A1

WO2021001244A1 - Peptide acetals for stabilising enzymes

Info

Publication number: WO2021001244A1
Application number: PCT/EP2020/067722
Authority: WO
Inventors: Allan F CUNNINGHAM; Stefan Jenewein; Gabriele BOENEMANN
Original assignee: Basf Se
Priority date: 2019-07-01
Filing date: 2020-06-24
Publication date: 2021-01-07
Also published as: BR112021023457A2; EP3994148A1; CN114008068A; JP2022538360A; US20220267699A1; MX2021015894A

Abstract

The present invention relates to a compound for stabilizing enzymes, the use of said compound for stabilizing an enzyme, a composition comprising said compound, a method of preparing the composition comprising said compound, a detergent composition comprising said compound and a method of preparing said compound.

Description

PEPTIDE ACETALS FOR STABILISING ENZYMES

The present invention relates to a compound for stabilizing enzymes, the use of said com pound for stabilizing an enzyme, a composition comprising said compound, a method of pre paring the composition comprising said compound, a detergent composition comprising said compound and a method of preparing said compound.

BACKGROUN D OF THE INVENTION

WO 98/13458, WO 94/04651, WO 98/13460, WO 95/25791, and WO 2009/118375 disclose liquid detergents with a subtilisin-type protease stabilized by a peptide aldehyde.

WO 2011/036153 discloses that the addition of a peptide aldehyde to a particulate subtil- isin-containing detergent can improve the detergency. WO 2013/004636 discloses a compo sition comprising a subtilisin and a peptide aldehyde hydrosulfite adduct.

WO 98/47523 and US 6,500,802 disclose peptidyl-2-amino-l-hydroxyalkanesulfonic acids and their use as protease inhibitors. US 5,436,229 discloses bisulfite adducts of L-arginine aldehyde derivatives and their use as thrombin inhibitors. US 4,691,007 discloses bisulfite adducts of tetrapeptide aldehydes useful as human leukocyte elastase inhibitors.

US 4,703,036, US 4,478,745 and US 5,578,574 disclose methods of preparing peptide alde hydes in dry form.

However, there is still a need for compounds which efficiently stabilize enzymes.

SUMMARY OF THE INVENTION

Aldehydes, particularly peptide aldehydes, used for enzyme stabilization are prone to inacti vation by chemical reactions. The inventors have found that the acetal form of an aldehyde, particularly the acetal form of a peptide aldehyde, is itself effective as an enzyme inhibitor and stabilizer, particularly as a protease inhibitor and stabilizer, and that it can also stabilize a second enzyme, if present. The inventors have found that said acetal is effective as en zyme inhibitor, particularly as protease inhibitor, and that it maintains its inhibitory and sta bilizing effect in a liquid detergent during storage. The addition of said acetals may also im prove the detergency (wash performance) of a protease-containing detergent, particularly a subtilisin-containing detergent.

Accordingly, the present invention relates to compound of formula (I) or a salt thereof

wherein R¹, R² and R³are each independently selected from the group consisting of hydrogen, op tionally substituted C^alkyl, optionally substituted C_2-6 alkenyl, optionally substituted C^g alkoxy, optionally substituted 3- to 12-membered cycloalkyl, and optionally substituted 6- to 10-membered aryl; or wherein each R¹, R² and R³ is independently selected as -(CH₂)₃- which is also attached to the nitrogen atom of-NH-C(H)- so that -N-C(H)R^1,2or3- forms a 5- membered heterocyclic ring;

R⁴and R⁵ are each independently selected from the group consisting of hydrogen, optionally substituted C^alkyl, optionally substituted C_2-6 alkenyl, optionally substituted C^alkoxy, optionally substituted C_1-4acyl, optionally substituted C^alkyl phenyl, and optionally substi tuted 6- to 10-membered aryl; or wherein R⁴and R⁵ are joined to form an optionally substi tuted 5- to 12-membered ring;

Z is selected from hydrogen, an N-terminal protection group, and one or more amino acid residues optionally comprising an N-terminal protection group.

In one embodiment R¹ and R² is a group such that NH-CHR^CO and NH-CHR²-CO is an L or D-amino acid residue of Gly, Ala, Val, Leu, lie, Met, Pro, Phe, Trp, Ser, Thr, Asp, Gin, Tyr,

Cys, Lys, Arg, His, Asn, Glu, m-tyrosine, 3,4-dihydroxyphenylalanine, Nva, or Nle.

In one embodiment R³ is a group such that NH-CHR³-CO is an L or D-amino acid residue of Gly, Ala, Val, Leu, lie, Met, Pro, Phe, Trp, Ser, Thr, Asp, Gin, Tyr, Cys, Lys, Arg, His, Asn, Glu, m-tyrosine, 3,4-dihydroxyphenylalanine, Nva, or Nle, or wherein R³ is (CH₃)₃SiCH₂.

In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Ala, Val, Gly, Arg, Leu, Phe or Thr.

In one embodiment R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala, Cys, Gly, Pro, Ser, Thr, Val, Nva or Nle.

In one embodiment R³ is a group such that NH-CHR³-CO is an L or D-amino acid residue of Tyr, m-tyrosine, 3,4-dihydroxyphenylalanine, Phe, Val, Ala, Met, Nva, Leu, lie or Nle.

In one embodiment R⁴ and R⁵are each independently selected from methyl (Me), ethyl (Et), isopropyl (/Pr) or isobutyl (/Bu), preferably from methyl or ethyl.

In one embodiment R⁴ and R⁵ are both methyl, ethyl, or isopropyl.

In one embodiment Z is an N-terminal protection group.

In one embodiment the N-terminal protection group is selected from benzyloxycarbonyl (Cbz), p-methoxybenzyl carbonyl (MOZ), benzyl (Bn), benzoyl (Bz), p-methoxybenzyl (PMB), p-methoxyphenyl (PMP), formyl, acetyl (Ac), methyloxy, alkoxycarbonyl, methoxycarbonyl (Moc), fluorenylmethyloxycarbonyl (Fmoc) or fe/V-butyloxycarbonyl (t-Boc).

The present invention further relates to the use of the compound as disclosed herein for stabilizing an enzyme. In one embodiment the enzyme is a hydrolase, preferably a protease. The present invention further relates to a composition comprising a compound as disclosed herein and an enzyme, preferably a hydrolase, more preferably a protease. In one embodi ment the protease is a serine protease and preferably is a subtilisin protease. In one em bodiment the composition further comprises a surfactant. In one embodiment the composi tion is in liquid or granular form. In one embodiment the composition comprises at least a second enzyme different from the first enzyme, preferably a lipase, protease, cutinase, am ylase, carbohydrase, cellulase, pectinase, pectate lyase, mannanase, arabinase, galac- tanase, xylanase, oxidase, laccase or peroxidase.

The present invention further relates to a method of preparing the composition as disclosed herein comprising the step of mixing the enzyme, preferably the hydrolase, more preferably the protease, the compound of formula (I) as disclosed herein.

The present invention further relates to a detergent composition comprising the compound as disclosed herein or the composition as disclosed herein and optionally a surfactant.

The present invention further relates to a method of preparing a compound of formula (I) comprising the steps:

a) providing a compound according to formula

b) converting the compound of step a) to

r the corresponding salt thereof

having the formula

c) reacting the compound or the corresponding salt thereof obtained in step b) with

d) optionally, converting the compound obtained in step

is not hydrogen;

wherein R¹ to R⁵ and Z are as defined herein.

DETAI LED DESCRI PTION OF TH E I NVENTION

Although the present invention wil l be described with respect to particu lar em bodiments, this description is not to be construed in a limiting sense.

Before describing in detail exemplary em bodiments of the present invention, definitions im portant for understanding the present invention are given. U nless stated otherwise or ap parent from the nature of the definition, the definitions apply to al l methods and uses de scribed herein.

As used in this specification and in the appended claims, the singular forms of "a" and "an" also include the respective plu rals un less the context clearly dictates otherwise. I n the con text of the present invention, the terms "about" and "approximately" denote an interval of accu racy that a person skil led in the art wil l understand to stil l ensu re the technical effect of the featu re in question. The term typical ly indicates a deviation from the indicated nu merical value of ± 20 %, preferably ± 15 %, more preferably ± 10 %, and even more prefera bly ± 5 %.

It is to be u nderstood that the term "comprising" is not limiting. For the pu rposes of the pre sent invention the term "consisting of" is considered to be a preferred embodiment of the term "com prising". If hereinafter a group is defined to com prise at least a certain num ber of embodiments, this is meant to also encom pass a group which preferably consists of these embodiments only.

Fu rthermore, the terms "first", "second", "third" or "(a)", "(b)", "(c)", "(d)" etc. and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or ch ronological order. It is to be u nderstood that the terms so used are interchangeable u nder appropriate circumstances and that the em bodiments of the invention described herein are capable of operation in other sequences than described or il lustrated herein. I n case the terms "first", "second", "third" or "(a)", "(b)", "(c)", "(d)", "i", "ii" etc. relate to steps of a method or use or assay there is no time or time interval coherence between the steps, i.e. the steps may be carried out simultaneously or there may be time intervals of seconds, minutes, hours, days, weeks, months or even years between such steps, u n less otherwise indicated in the application as set forth herein above or below. It is to be understood that this invention is not limited to the particular methodology, proto cols, reagents etc. described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention that will be limited only by the ap pended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

The term "alkyl" as used by itself or as part of another group refers to a straight- or branched-chain aliphatic hydrocarbon containing one to eight carbon atoms {i.e., C^g alkyl) or the number of carbon atoms designated {i.e., a C₄ alkyl such as methyl, a C₂ alkyl such as ethyl, a C₃ alkyl such as propyl or isopropyl, etc.). In one embodiment, the alkyl group is chosen from a straight chain C^g alkyl group. In another embodiment, the alkyl group is chosen from a branched chain C_3-8 alkyl group. In another embodiment, the alkyl group is chosen from a straight chain alkyl group. In another embodiment, the alkyl group is chosen from a branched chain C_3-6 alkyl group. In another embodiment, the alkyl group is chosen from a straight chain C_4-4 alkyl group. In another embodiment, the alkyl group is cho sen from a branched chain C_3-4 alkyl group. In another embodiment, the alkyl group is cho sen from a straight or branched chain C_3-4 alkyl group. Non-limiting exemplary 0_4-8 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert- butyl, /s -butyl, 3-pen- tyl, hexyl, heptyl, and octyl. Non-limiting exemplary C_4-4 a I ky I groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert- butyl, and /se-butyl.

The term "optionally substituted alkyl" as used herein by itself or as part of another group means that the alkyl as defined above is either unsubstituted or substituted with one or more (e.g., one, two, or three) substituents independently selected from the group consist ing of amino, (alkyl)amino, (al kyl) carbonyl , (aryl)carbonyl, (alkoxy)carbonyl, [(alkoxy)car- bonyl]amino, carboxy, aryl, heteroaryl, ureido, guanidino, halogen, sulfonamido, hydroxyl,

(al kyl) su Ifany I , nitro, haloalkoxy, aryloxy, aralkyloxy, (al kyl) su Ifony I , (cycloa I kyl)su Ifonyl , (aryl)sulfonyl, cycloalkyl, sulfanyl, caboxamido, heterocyclyl, (heterocyclyl)sulfonyl, amides, (alkyl)phosphates, nitrile, (alkyl)ethers, (alkyl)esters, and silyl, such as alkyl silyl. In one em bodiment, the optionally substituted alkyl is substituted with two substituents. In another embodiment, the optionally substituted alkyl is substituted with one substituent. Non-limit ing exemplary optionally substituted alkyl groups include -CH(CH₃)CONH₂, -CH₂CH₂N0₂, - CH(OH)CH₂(OH), -CH(OH)CH(OH)CONH₂, -CFg, -CH₂CH₂C0₂H, -CH₂Ph-OH, -CH₂SH, - CH₂C0₂H, -CH(CHg)OH, -CH₂CH₂_CH₂NC(=NH)NH₂, -CH₂CH₂SCH₃, -CH₂CH₂COPh, and - CH₂C₆H_n.

As used herein, the term "cycloalkyl" by itself or as part of another group refers to saturated or partially unsaturated (containing one or two double bonds) cyclic aliphatic hydrocarbons containing one to three rings having from three to twelve carbon atoms (i.e., C_3-12 cycloalkyl) or the number of carbons designated. In one embodiment, the cycloalkyl group has two rings. In one embodiment, the cycloalkyl group has one ring. In another embodiment, the cycloalkyl group is a saturated or unsaturated C_3-8 cycloalkyl group. In another embodiment, the cycloalkyl group is a saturated or unsaturated C_5-6 cycloalkyl group. Non-limiting exem plary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, cyclopentenyl, and cyclohexenyl. As used herein, the term "optionally substituted cycloalkyl" by itself or as part of another group means that the cycloalkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of halo, ni tro, cyano, hydroxyl, amino, (alkyl)amino, (dialkyl)amino, haloalkyl, (hyd roxyl) a I ky I , (dihy- d roxy) a I kyl , alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, (al- kyl)carbonyl, (aryl)carbonyl, (a I kyl)su Ifonyl , arylsulfonyl, ureido, guanidino, carboxy, (car- boxy) a I kyl , alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, (a I koxy) a I kyl , (amino)alkyl, (hydroxyl)alkylamino, (a I ky I a m i n o) a I ky I , (dial kyl a m i n o) a I ky I , (cyano)alkyl, (car- boxamido)alkyl, (a I kyl) su Ifa nyl , (heterocyclo)alkyl, (heteroaryl)alkyl, (alkoxy)carbonyl, mer- captoalkyl, amides, (alkyl)phosphates, nitrile, (alkyl)ethers, (alkyl)esters, and silyl, such as alkyl silyl. In one embodiment, the optionally substituted cycloalkyl is substituted with two substituents. In another embodiment, the optionally substituted cycloalkyl is substituted with one substituent. Non-limiting exemplary optionally substituted cycloalkyl groups in clude:

As used herein, the term "alkoxy" by itself or as part of another group refers to an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, or option ally substituted alkynyl attached to a terminal oxygen atom. In one embodiment, the alkoxy group is chosen from a C^g alkoxy group. In another embodiment, the alkoxy group is cho sen from a C^g alkyl attached to a terminal oxygen atom, e.g., methoxy, ethoxy, butoxy, and teAAbutoxy.

As used herein, the term "alkenyl" by itself or as part of another group refers to an alkyl group as defined above containing one, two or three carbon-to-carbon double bonds. In one embodiment, the alkenyl group is chosen from a C_2-6 alkenyl group. In another embodi ment, the alkenyl group is chosen from a C_2-4 alkenyl group. Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.

As used herein, the term "optionally substituted alkenyl" by itself or as part of another group means the alkenyl as defined above is either unsubstituted or substituted with one, two or three substituents independently selected from the group consisting of halo, nitro, cyano, hydroxyl, amino, (alkyl)amino, (dialkyl)amino, haloalkyl, (hydroxy)alkyl, (dihydroxy)alkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, (alkyl)sulfanyl, carboxamido, sulfonamido, (alkyl)car- bonyl, (aryl)carbonyl, (a I ky I) su Ifonyl , (aryl)sulfonyl, ureido, guanidino, carboxy, (carboxy)al- kyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, amides, (al kyl) phos phates, nitrile, (alkyl)ethers, (alkyl)esters, and silyl, such as alkyl silyl.

As used herein, the term "alkynyl" by itself or as part of another group refers to an alkyl group as defined above containing one to three carbon-to-carbon triple bonds. In one em bodiment, the alkynyl has one carbon-to-carbon triple bond. In one embodiment, the alkynyl group is chosen from a C_2-6 alkynyl group. In another embodiment, the alkynyl group is cho sen from a C_2-4 alkynyl group. Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.

As used herein, the term "optionally substituted alkynyl" by itself or as part of another group means the alkynyl as defined above is either unsubstituted or substituted with one, two or three substituents independently selected from the group consisting of halo, nitro, cyano, hydroxyl, amino, alkylamino, dialkylamino, haloalkyl, (hydroxy)alkyl, (dihydroxy)alkyl, alkoxy, haloalkoxy, alkeneoxy, aryloxy, aralkyloxy, (alkyl)sulfanyl, carboxamido, sulfonamido, alkyl- carbonyl, arylcarbonyl, a I kylsu Ifonyl , arylsu Ifonyl, ureido, guanidino, carboxy, (carboxy)alkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, amides, (alkyl)phosphates, nitrile, (alkyl)ethers, (alkyl)esters, and silyl, such as alkyl silyl.

As used herein, the term "aryl" by itself or as part of another group refers to a monocyclic or bicyclic aromatic ring system having from six to fourteen carbon atoms (i.e., C₆-C₁₄aryl). Non-limiting exemplary aryl groups include phenyl (abbreviated as "Ph"), naphthyl, phenan- thryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups. In one em bodiment, the aryl group is chosen from phenyl or naphthyl.

As used herein, the term "optionally substituted aryl" by itself or as part of another group means that the aryl as defined above is either unsubstituted or substituted with one to five substituents independently selected from the group consisting of halo, nitro, cyano, hy droxyl, amino, alkylamino, dialkylamino, haloalkyl, (hydroxy)alkyl, (dihydroxy)alkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, (al- kyl)carbonyl, (aryl)carbonyl, (a I kyl)su Ifonyl , (aryl)sulfonyl, ureido, guanidino, carboxy, car- boxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, (a I koxy) a I ky I , (amino)alkyl, [(hyd roxy I) a I ky I] a m i n o, [(a I kyl) a mi no]a I ky I , [(dial ky I) a m i no) a I ky I , (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (cycloalkylamino)alkyl, (halo(C₁- C₄)al koxy)al kyl, (heteroaryl)alkyl, amides, (alkyl)phosphates, nitrile, (alkyl)ethers, (alkyl)es- ters, and silyl, such as alkyl silyl. In one embodiment, the optionally substituted aryl is an optionally substituted phenyl. In one embodiment, the optionally substituted phenyl has four substituents. In another embodiment, the optionally substituted phenyl has three sub stituents. In another embodiment, the optionally substituted phenyl has two substituents.

In another embodiment, the optionally substituted phenyl has one substituent. Non-limiting exemplary substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluoro- phenyl, 2-chlorophenyl, 2-bromophenyl, 3-methylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chloro- phenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl, 3-methoxyphenyl, 2-ethyl, 3- methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl 3,5-di-methylphenyl, 3,5-di- methoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, and 3-chloro-4-fluorophenyl. The term optionally substituted aryl is meant to include groups having fused optionally substituted cycloalkyl and fused optionally substituted heterocyclo rings. Examples include:

As used herein, the term "heteroaryl" or "heteroaromatic" refers to monocyclic and bicyclic aromatic ring systems having 5 to 14 ring atoms (i.e., C₅-C₁₄ heteroaryl) and 1, 2, 3, or 4 het eroatoms independently chosen from oxygen, nitrogen and su lfur. I n one em bodiment, the heteroaryl has three heteroatoms. I n another em bodiment, the heteroaryl has two heteroa toms. I n another em bodiment, the heteroaryl has one heteroatom. I n one embodiment, the heteroaryl is a C₅ heteroaryl. I n another embodiment, the heteroaryl is a C₆ heteroaryl. Non-limiting exemplary heteroaryl grou ps include thienyl, benzo[b]thienyl, naphtho[2,3- b] th ie ny I , thianth renyl, fu ryl, benzofuryl, pyranyl, isobenzofu ranyl, benzooxazonyl, chrome- nyl, xanthenyl, 2 AZ-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyri- dazinyl, isoindolyl, 3 /V- i n d o I y I , indolyl, indazolyl, pu rinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cin nolinyl, quinazolinyl, pteridinyl, 4a AZ-carbazolyl, carbazolyl, b -carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanth rolinyl, phenazinyl, thiazolyl, isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl, and phenoxazinyl. I n one embodiment, the heteroaryl is chosen from thienyl ( e thien-2-yl and thien-3-yl), fu ryl ( eg 2-fu ryl and 3-furyl), pyr rolyl ( eg lH-pyrrol-2-yl and 1 H - pyrrol -3-yl) , imidazolyl {e.g., 2H-imidazol-2-yl and 2H-im- idazol-4-yl), pyrazolyl {e.g., l H-pyrazol-3-yl, l H-pyrazol-4-yl, and l H-pyrazol-5-yl), pyridyl {e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl {e.g., pyrimidin-2-yl, pyrimidin- 4-yl, and pyrimidin-5-yl), thiazolyl {e.g., thiazol-2-yl, thiazol -4-y I , and thiazol-5-yl), isothia zolyl {e.g., isoth iazol -3-y I , isothiazol-4-yl, and isothiazol -5-y I) , oxazolyl {e.g., oxazol-2-yl, ox- azol-4-yl, and oxazol-5-yl) and isoxazolyl {e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5- yl). The term "heteroaryl" is also meant to include possible N-oxides. Exemplary N-oxides include pyridyl N-oxide and the like.

As used herein, the term "optional ly su bstituted heteroaryl" by itself or as part of another group means that the heteroaryl as defined above is either u nsubstituted or su bstituted with one to four su bstituents, e.g, one or two su bstituents, independently selected from the group consisting of halo, nitro, cyano, hyd roxy, amino, (al kyl)amino, (dial kyl)amino, haloal- kyl, (hydroxy)al kyl, (dihyd roxy)al kyl, al koxy, haloal koxy, aryloxy, aral kyloxy, al kylthio, carbox- amido, sulfonamido, (al kyl)carbonyl, (aryl)carbonyl, (a I ky I) su Ifonyl , (aryl)sulfonyl, u reido, guanidino, carboxy, (carboxy)al kyl, al kyl, cycloal kyl, al kenyl, a I ky ny I , aryl, heteroaryl, hetero- cyclo, (a I koxy) a I ky I , (amino)al kyl, [(hyd roxy I) a I ky I] a m i no, [(a I ky I) a mi no]a I ky I , [(dial ky I) am i no] al kyl , (cyano)al kyl, (carboxamido)al kyl, mercaptoal kyl, (heterocyclo)al kyl, (het- e roa ry I) a I ky I , and the like. I n one em bodiment, the optional ly su bstituted heteroaryl has one su bstituent.

For the pu rpose of the present invention, compou nds com prising a stereocenter are consid ered to encom pass and disclose both enantiomers, u nless specifical ly indicated. I n case that a com pound com prises more than one stereocenter, al l diastereomers as wel l as enan tiomers are considered to be encompassed and disclosed, u nless specifical ly indicated. If reference is made to a composition or mixture com prising a com pou nd according to the pre sent invention, it is understood that the compound can be present either as enantiomeri- cal ly and/or diastereomerical ly pu re compound or as a mixtu re of enantiomers and/or dia stereomers, for example as a racemic mixtu re of the L or D-enantiomers of the amino acid residues as defined hereinafter. The same applies with regard to the synthesis of the com- pounds of the present invention, which compounds can be obtained either as enantiomeri- cally and/or diastereomerically pure compounds or as a mixture of enantiomers and/or dia- stereomers, for example as a racemic mixture of the L or D-enantiomers of the amino acid residue as defined hereinafter.

As discussed above, the present invention relates to a compound of formula (I) or a salt thereof

wherein

R¹, R² and R³are each independently selected from the group consisting of hydrogen, op tionally substituted C^alkyl, optionally substituted C_2-6 alkenyl, optionally substituted C^g alkoxy, optionally substituted 3- to 12-membered cycloalkyl, and optionally substituted 6- to 10-membered aryl; or wherein each R¹, R² and R³ is independently selected as -(CH₂)₃- which is also attached to the nitrogen atom of-NH-C(H)- so that -N-C(H)R^1,2or3- forms a 5- membered heterocyclic ring;

R⁴and R⁵ are each independently selected from the group consisting of hydrogen, optionally substituted C^alkyl, optionally substituted C_2-6 alkenyl, optionally substituted C^alkoxy, optionally substituted C_1-4acyl, optionally substituted C^alkyl phenyl (e.g. benzyl), and op tionally substituted 6- to 10-membered aryl; or wherein R⁴ and R⁵ are joined to form an op tionally substituted 5- or 6-membered ring;

Preferably, each of R¹ and R² is a group such that NH-CHF -CO and NH-CHR²-CO is an L or D-amino acid residue. L or D-amino acid residues include the L or D-form of glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine (lie), methionine (Met), proline (Pro), phenylalanine (Phe), tryptophane (Trp), serine (Ser), threonine (Thr), aspartic acid (Asp), glutamine (Gin), tyrosine (Tyr), cysteine (Cys), lysine (Lys), arginine (Arg), histidine (His), asparagine (Asn), glutamic acid (Glu), m-tyrosine, 3,4-dihydroxyphenylalanine, norvaline (Nva) and norleucine (Nle).

Preferably, R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Gly, Ala, Val, Leu, lie, Met, Pro, Phe, Trp, Ser, Thr, Asp, Gin, Tyr, Cys, Lys, Arg, His, Asn, Glu, m-tyro- sine, 3,4-dihydroxyphenylalanine, Nva, or Nle. More preferably, R¹ is a group such that NH- CHR^CO is an L or D-amino acid residue of Ala, Val, Gly, Arg, Leu, Phe, lie, His or Thr. Even more preferably, R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Ala, Val, Gly, Arg, Leu, lie or His. Preferably, R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Gly, Ala, Val, Leu, lie, Met, Pro, Phe, Trp, Ser, Thr, Asp, Gin, Tyr, Cys, Lys, Arg, His, Asn, Glu, m-tyro- sine, 3,4-dihydroxyphenylalanine, Nva, or Nle. More preferably, R² is a group such that NH- CHR²-CO is an L or D-amino acid residue of Ala, Cys, Gly, Pro, Ser, Thr, Val, Nva or Nle.

Even more preferably, R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala, Gly, Pro or Val.

In one embodiment, each of R¹ and R² is a group such that NH-CHR^CO and NH-CHR²-CO is an L or D-amino acid residue of Gly, Ala, Val, Leu, lie, Met, Pro, Phe, Trp, Ser, Thr, Asp, Gin, Tyr, Cys, Lys, Arg, His, Asn, Glu, m-tyrosine, 3,4-dihydroxyphenylalanine, Nva or Nle.

In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Ala, Val, Gly, Arg, Leu, lie or His and R² is a group such that NH-CHR²-CO is an L or D- amino acid residue of Ala. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Ala, Val, Gly, Arg, Leu, lie or His and R² is a group such that NH- CHR²-CO is an L or D-amino acid residue of Gly. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Ala, Val, Gly, Arg, Leu, lie or His and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Pro. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Ala, Val, Gly, Arg, Leu, lie or His and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Val.

In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Ala and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala, Gly, Pro or Val. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid res idue of Val and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala, Gly, Pro or Val. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Gly and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala, Gly, Pro or Val. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D- amino acid residue of Arg and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala, Gly, Pro or Val. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Leu and R² is a group such that NH-CHR²-CO is an L or D- amino acid residue of Ala, Gly, Pro or Val. In one embodiment R¹ is a group such that NH- CHR^CO is an L or D-amino acid residue of lie and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala, Gly, Pro or Val. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of His and R² is a group such that NH- CHR²-CO is an L or D-amino acid residue of Ala, Gly, Pro or Val.

In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Gly and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Val and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala. In one em bodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Arg and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala. In one embodi ment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Gly and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Gly. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Arg and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Val. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Leu and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Val. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Ala and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Val. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of His and R² is a group such that NH- CHR²-CO is an L or D-amino acid residue of Ala. In one embodiment R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of lie and R² is a group such that NH-CHR²- CO is an L or D-amino acid residue of Pro. In one embodiment R¹ is a group such that NH- CHf -CO is an L or D-amino acid residue of lie and R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Gly.

In one embodiment, R³ is a group selected from optionally substituted C^alkyl, such as CH₂Si(CH₃)₃, C^g alkylphosphates such as (CH₂)_nPO(OR)₂, 0_3-8 a I ky I nitriles such as CH₂CN, C^g alkylsulfones such as CH₂S0₂R, C_j^alkylethers such as (CH₂)_nOR, C^g alkylesters such as CH₂C0₂R, and C^g alkylamides; optionally substituted C_j^alkoxy, optionally substituted 3- to 12-membered cycloalkyl, such as cyclohexylmethyl; and optionally substituted 6- to 10-membered aryl, wherein R is independently selected from the group consisting of hydro gen, optionally substituted C^alkyl, optionally substituted C_j^alkoxy, optionally substituted 3- to 12-membered cycloalkyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 6- to 10-membered heteroaryl and n is an integer from 1 to 8, i.e.1, 2, 3, 4, 5, 6,

7 or 8.

Preferably, R³ is a group such that NH-CHR³-CO is an L or D-amino acid residue of Tyr, m- tyrosine, 3,4-dihydroxyphenylalanine, Phe, Val, Ala, Met, Nva, Leu, lie or Nle or other non natural amino acids carrying alkyl groups. More preferably, R³ is a group such that NH- CHR³-CO is an L or D-amino acid residue of Tyr, Phe, Val, Ala or Leu.

In one embodiment, R¹, R² and R³ is a group such that NH-CHFT-CO, NH-CHR²-CO and NH- CHR³-CO each is an L or D-amino acid residue of Gly, Ala, Val, Leu, lie, Met, Pro, Phe, Trp, Ser, Thr, Asp, Gin, Tyr, Cys, Lys, Arg, His, Asn, Glu, m-tyrosine, 3,4-dihydroxyphenylalanine, Nva or Nle.

In a preferred embodiment, R¹ and R² is a group such that NH-CHR^CO and NH-CHR²-CO each is an L or D-amino acid residue of Ala, Cys, Gly, Pro, Ser, Thr, Val, Nva or Nle, and R³ is a group such that NH-CHR³-CO is an L or D-amino acid residue of Tyr, m-tyrosine, 3,4-dihy droxyphenylalanine, Phe, Val, Ala, Met, Nva, Leu, lie or Nle.

In a preferred embodiment, R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Gly or Val, R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala, and R³ is a group such that NH-CHR³-CO is an L or D-amino acid residue of Tyr, Ala, or Leu. In a particularly preferred embodiment, R¹ is a group such that NH-CHR^CO is an L or D- amino acid residue of Val, R² is a group such that NH-CHR²-CO is an L or D-amino acid res idue of Ala, and R³ is a group such that NH-CHR³-CO is an L or D-amino acid residue of Leu.

In another particularly preferred embodiment, R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Gly, R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala, and R³ is a group such that NH-CHR³-CO is an L or D-amino acid resi due of Tyr.

In another particularly preferred embodiment, R¹ is a group such that NH-CHR^CO is an L or D-amino acid residue of Val, R² is a group such that NH-CHR²-CO is an L or D-amino acid residue of Ala, and R³ is a group such that NH-CHR³-CO is an L or D-amino acid resi due of Ala.

In a particularly preferred embodiment, R¹ is a group such that NH-CHR^CO is an L or D- amino acid residue of Val, R² is a group such that NH-CHR²-CO is an L or D-amino acid res idue of Ala, and R³ is a group such that NH-CHR³-CO is an L or D-amino acid residue of Norleucine.

In a particularly preferred embodiment, R¹ is a group such that NH-CHR^CO is an L or D- amino acid residue of Val, R² is a group such that NH-CHR²-CO is an L or D-amino acid res idue of Ala, and R³ is a group such that NH-CHR³-CO is an L or D-amino acid residue of Norvaline.

In one embodiment, R⁴ and R⁵are each independently selected from hydrogen, methyl, ethyl, i-propyl, n-propyl, i-butyl, s-butyl, n-butyl, i-pentyl, 2-pentyl, 3-pentyl, neopentyl, cyclopen tyl, cyclohexyl, and benzyl.

Preferably, R⁴ and R⁵are each independently selected from methyl, ethyl, isopropyl, 2-butyl or 3-pentyl. More preferably, R⁴ and R⁵ are both methyl, ethyl, isopropyl, 2-butyl or 3-pentyl.

In another embodiment, R⁴ and R⁵are joined to form an optionally substituted 5- to 12- membered ring. Examples of the resulting ring are substituted or unsubstituted dioxolanes, dioxanes, trioxanes. Preferably, the resulting ring is 1,3-dioxolane, 4-methyl-l,3-dioxolane, 4- hyd roxy methyl- 1,3 -dioxo lane 4,4-dimethyl -1,3-dioxolane, 4,5 -dimethyl -1,3-dioxolane, 4,4,5-trimethyl-l,3-dioxolane, 4,4,5,5-tetramethyl-l,3-dioxolane, substituted or unsubsti tuted 1,3-dioxane, 1,3,5-trioxane.

Z is selected from hydrogen, an N-terminal protection group, and one or more amino acid residues optionally comprising an N-terminal protection group. Preferably, Z is an N-termi- nal protection group.

The N-terminal protection group may be selected from formyl, acetyl (Ac), benzoyl (Bz), tri- fluoroacetyl, fluorenylmethyloxycarbonyl (Fmoc), methoxysuccinyl, aromatic and aliphatic urethane protecting groups, benzyloxycarbonyl (Cbz), fe/T-butyloxycarbonyl (Boc), adaman- tyloxycarbonyl, /?-methoxybenzyl carbonyl (MOZ), benzyl (Bn), /?-methoxybenzyl (PM B) or p- methoxyphenyl (PM P), methoxycarbonyl (Moc); methoxyacetyl (Mac); methyl carbamate, a methylamino carbonyl/methyl urea group, tityl (Trt), 3,5-dimethoxyphenylisoproxycarbonyl (Ddz), 2-(4-biphenyl)isopropoxycarbonyl (Bpoc), 2-nitrophenylsulfenyl (Nps), 2-(4-nitro- phenylsulfony ethoxycarbonyl (Nsc), l,l-dioxobenzo[b]thiophene-2-ylmethyloxycarbonyl (Bsmoc), (l,l-dioxonaphtho[l,2-b]thiophene-2-yl)methyloxycarbonyl ( a -Nsmoc), 1 -(4,4- dimethyl-2,6-dioxocyclohex-l-ylidene)-3-methylbutyl (ivDde), 2,7-di-tert-butyl-Fmoc (Fmoc*), 2-fluoro-Fmoc (Fmoc(2F)), 2-monoisooctyl-Fmoc (mio-Fmoc) and 2,7 -d i isooctyl - Fmoc (dio-Fmoc), tetrachlorophthaloyl (TCP), 2-phenyl(methyl)sulfonio)ethyloxycarbonyl tetrafluoroborate (Pms), ethanesulfonylethoxycarbonyl (Esc), 2-(4-sulfophenylsulfonyl)eth- oxycarbonyl (Sps), allyloxycarbonyl (Alloc), o-nitrobenzenesulfonyl (oNBS), 2,4-dinitroben- zenesulfonyl (dN BS), Benzothiazole-2-sulfonyl (Bts), 2,2,2-trichloroethyloxycarbonyl (Troc), dithiasuccinoyl (Dts), p-nitrobenzyloxycarbonyl (pNZ), a -Azidoacids, Propargyloxycarbonyl (Poc), o-Nitrobenzyloxycarbonyl (oNZ), 4-Nitroveratryloxycarbonyl (NVOC), 2 - (2 - N itro- phenyl) propyloxycarbonyl (NPPOC), 2 -(3,4- Methyl enedioxy-6-n itro phenyl) propyl oxycar- bonyl (MN PPOC), 9-(4-Bromophenyl)-9-fluorenyl (BrPhF), Azidomethyloxycarbonyl (Azoc), Hexafluoroacetone (HFA), 2-Chlorobenzyloxycarbonyl (Cl-Z), Trifluoroacetyl (tfa), 2-(Me- thylsulfony ethoxycarbonyl (Msc), Tetrachlorophthaloyl (TCP), Phenyldisulpha- nylethyloxycarbonyl (Phdec), 2-Pyridyldisulphanylethyloxycarbonyl (Pydec), or 4-Methyltrityl (Mtt).

If Z is one or more amino acid residue(s) comprising an N-terminal protection group, the N- terminal protection group is preferably a small aliphatic group, e.g., formyl, acetyl, fluorenyl- methyloxycarbonyl (Fmoc), fe/T-butyloxycarbonyl (Boc), methoxycarbonyl (Moc); methoxya cetyl (Mac); methyl carbamate or a methylamino carbonyl/methyl urea group. In the case of a tripeptide, the N-terminal protection group is preferably a bulky aromatic group such as benzoyl (Bz), benzyloxycarbonyl (Cbz), /7-methoxybenzyl carbonyl (MOZ), benzyl (Bn), p- methoxybenzyl (PM B) or p-methoxyphenyl (PMP).

Further suitable N-terminal protection groups are described in Greene’s Protective Groups in Organic Synthesis, Fifth Edition by Peter G. M. Wuts, published in 2014 by John Wiley & Sons, Inc and in Isidro-Flobet et a I . , Amino Acid-Protecting Groups, Chem. Rev. 2009 109(6), 2455-2504.

Preferably, the N-terminal protection group is selected from benzyloxycarbonyl (Cbz), p- methoxybenzyl carbonyl (MOZ), benzyl (Bn), benzoyl (Bz), /7-methoxybenzyl (PMB), /?-meth- oxyphenyl (PMP), formyl, acetyl (Ac), methyloxy, alkoxycarbonyl, methoxycarbonyl, fluo- renylmethyloxycarbonyl (Fmoc), or fe/T-butyloxycarbonyl (Boc).

As discussed above, the present invention further relates to the use of the compound ac cording to formula (I) for stabilizing an enzyme.

In one embodiment, the enzyme is a hydrolase. Hydrolases are a class of enzymes that is commonly used as biochemical catalysts that utilize water to break a chemical bond. In a preferred embodiment, the enzyme is selected from a lipase, protease, cutinase, amylase, carbohydrase, cellulase, pectinase, pectate lyase, mannanase, arabinase, galactanase, xy- lanase, oxidase, laccase, and peroxidase. Preferred hydrolases include esterases, such as nucleases, phosphodiesterases, lipases, and phosphatases; proteases, such as serine pro teases; and glycoside hydrolases, such as cellulases and amylases.

In a preferred embodiment, the enzyme is a protease or a lipase.

Proteases (also known as proteinases or peptidases) hydrolyze the peptide bond between amino acid residues in a polypeptide chain. Proteases may be specific and limited to one or more recognition sites within a protein, or they may be nonspecific, digesting proteins into individual amino acids.

Proteases are members of class EC 3.4. Proteases include aminopeptidases (EC

3.4.11), dipeptidases (EC 3.4.13), dipeptidyl-peptidases and tripeptidyl-peptidases (EC 3.4.14), peptidyl-dipeptidases (EC 3.4.15), serine-type carboxypeptidases (EC 3.4.16), me- tallocarboxypeptidases (EC 3.4.17), cysteine-type carboxypeptidases (EC 3.4.18), omega peptidases (EC

3.4.19), serine endopeptidases (EC 3.4.21), cysteine endopeptidases (EC 3.4.22), aspartic endopeptidases (EC 3.4.23), metallo-endopeptidases (EC 3.4.24), threonine endopeptidases (EC 3.4.25), endopeptidases of unknown catalytic mechanism (EC 3.4.99).

Commercially available protease enzymes include but are not limited to Lavergy™ Pro (BASF); Alcalase^®, Blaze^®, Duralase™, Durazym™, Relase^®, Relase^® Ultra, Savinase^®, Savinase^® Ultra, Primase^®, Polarzyme^®, Kannase^®, Liquanase^®, Liquanase^® Ultra,

Ovozyme^®, Coronase^®, Coronase^® Ultra, Neutrase^®, Everlase^® and Esperase^® (Novozymes A/S), those sold under the tradename Maxatase^®, Maxacal^®, Maxapem^®, Purafect^®, Pura- fect^® Prime, Purafect MA^®, Purafect Ox^®, Purafect OxP^®, Puramax^®, Properase^®, FN2^®, FN3^®, FN e^®, Eraser^®, Ultimase^®, Opticlean^®, Effectenz^®, Preferenz^® and O pti - mase^® (D ont), Axapem™ (Gist-Brocases N.V.), Bacillus lentus Alkaline Prote ase, and

(Bacillus

subtilisin) from Kao.

Proteases can be classified by three criteria: the reaction catalyzed, the chemical nature of the catalytic site, and their evolutionary relationships. Endopeptidases cleave the target protein internally. Exopeptidases remove single amino acids from either the amino- or car- boxy-terminal end of a protein. Exopeptidases are divided into carboxypeptidases or ami nopeptidases depending on whether they digest proteins from the carboxy- or amino-termi nus, respectively.

Proteases are also classified based on their catalytic site architecture. In that regard, prote ases can be classified into seven broad groups comprising serine proteases, cysteine prote ases, threonine proteases, aspartic proteases, glutamic proteases, metalloproteases, and asparagine peptide lyases. Serine proteases have a serine in their active site that covalently attaches to one of the protein fragments as an enzymatic intermediate. This class includes the chymotrypsin family (chymotrypsin, trypsin, and elastase) and the subtilisin family. Cys teine proteases have a similar mechanism as serine proteases, but use cysteine rather than serine. They include plant proteases (papain from papaya, and bromelain from pineapple) as well as mammalian proteases such as calpains. Aspartic proteases have two essential aspartic acid residues that are close together in the active site although far apart in the pro tein sequence. This family includes the digestive enzymes pepsin and chymosin. Metal I o- proteases use metal ion cofactors to facilitate protein digestion and include thermolysin. Threonine proteases have threonine in the active site.

At least one protease may be selected from serine proteases (EC 3.4.21). Serine proteases or serine peptidases (EC 3.4.21) are characterized by having a serine in the cata lytica I ly ac tive site, which forms a covalent adduct with the substrate during the catalytic reaction. A serine protease may be selected from the group consisting of chymotrypsin (e.g., EC

3.4.21.1), elastase (e.g., EC 3.4.21.36), elastase (e.g., EC 3.4.21.37 or EC 3.4.21.71), granzyme (e.g., EC 3.4.21.78 or EC 3.4.21.79), kallikrein (e.g., EC 3.4.21.34, EC 3.4.21.35, EC 3.4.21.118, or EC 3.4.21.119,) plasmin (e.g., EC 3.4.21.7), trypsin (e.g., EC 3.4.21.4), thrombin (e.g., EC 3.4.21.5,) and subtilisin (also known as subtilopeptidase, e.g., EC 3.4.21.62), the latter hereinafter also being referred to as“subtilisin”.

A sub-group of the serine proteases tentatively designated subtilases has been proposed by Siezen et al. (1991), Protein Eng. 4:719-737 and Siezen et al. (1997), Protein Science 6:501- 523. They are defined by homology analysis of more than 170 amino acid sequences of ser ine proteases previously referred to as subtilisin-like proteases. A subtilisin was previously often defined as a serine protease produced by Gram-positive bacteria or fungi, and accord ing to

Siezen et al. now is a subgroup of the subtilases. A wide variety of subtilases have been identified, and the amino acid sequence of a number of subtilases has been determined. For a more detailed description of such subtilases and their amino acid sequences reference is made to Siezen et al. (1997), Protein Science 6:501-523.

The subtilases may be divided into 6 sub-divisions, i.e. the subtilisin family, thermitase fam ily, the proteinase K family, the lantibiotic peptidase family, the kexin family and the py roly- si n family.

A subgroup of the subtilases are the subtilisins which are serine proteases from the family S8 as defined by the MEROPS database (merops.sanger.ac.uk). Peptidase family S8 con tains the serine endopeptidase subtilisin and its homologues.

Prominent members of family S8, subfamily A are: Subtilisin Carlsberg (S08.001), Subtilisin lentus (S08.003), Thermitase (S08.007), Subtilisin BPN’ (S08.034), Subtilisin DY (S08.037), Alkaline peptidase (S08.038), Subtilisin ALP 1 (S08.045), Subtilisin sendai (S08.098) and Al kaline elastase YaB (S08.157).

Parent proteases of the subtilisin type (EC 3.4.21.62) and variants may be bacterial prote ases. Said bacterial protease may be a Gram-positive bacterial polypeptide such as a Bacil lus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus, or Streptomyces protease, or a Gram-negative bacterial polypeptide such as a Campylobacter, E. coli, Flavobacterium, Fusobacterium, Helicobacter, llyobacter, Neisseria, Pseudomonas, Salmonella, or Ureaplasma protease. A review of this family is provided, for example, in "Subtilases: Subtilisin-like Proteases" by R. Siezen, pages 75-95 in "Subtilisin enzymes", edited by R. Bott and C. Betzel, New York, 1996.

At least one protease may be selected from the following: subtilisin from Bacillus amyloliq- uefaciens BPN' (described by Vasantha et al. (1984) J. Bacteriol. 159, p. 811-819 and JA Wells et al. (1983) in Nucleic Acids Research, 11, p. 7911-7925); subtilisin from Bacillus li- cheniformis

(subtilisin Carlsberg; disclosed in EL Smith et al. (1968) J. Biol Chem, 243, pp. 2184-2191, and Jacobs et al. (1985) in Nucl. Acids Res, 13, p. 8913-8926); subtilisin PB92 (original se quence of the alkaline protease PB92 is described in EP 283075 A2); subtilisin 147 and/or 309 (Esperase^®, Savinase^®, respectively) as disclosed in WO 89/06279; subtilisin from Ba cillus lentus as disclosed in WO 91/02792, such as from Bacillus lentus DSM 5483 or the variants of Bacillus lentus DSM 5483 as described in WO 95/23221; subtilisin from Bacillus alcalophilus (DSM 11233) disclosed in DE 10064983; subtilisin from Bacillus gibsonii (DSM 14391) as disclosed in WO 2003/054184; subtilisin from Bacillus sp. (DSM 14390) disclosed in WO 2003/056017; subtilisin from Bacillus sp. (DSM 14392) disclosed in WO

2003/055974; subtilisin from Bacillus gibsonii (DSM 14393) disclosed in WO 2003/054184; subtilisin having SEQ I D NO: 4 as described in WO 2005/063974; subtilisin having SEQ I D NO: 4 as described in WO 2005/103244; subtilisin having SEQ I D NO: 7 as described in WO 2005/103244; and subtilisin having SEQ ID NO: 2 as described in application DE

102005028295.4.

At least one subtilisin may be subtilisin 309 (which might be called Savinase^® herein) as disclosed as sequence a) in Table I of WO 89/06279 or a variant which is at least 80% iden tical thereto and has proteolytic activity.

Proteases are known as comprising the variants described in: WO 92/19729, WO 95/23221, WO 96/34946, WO 98/20115, WO 98/20116, WO 99/11768, WO 01/44452, WO 02/088340, WO 03/006602, WO 2004/03186, WO 2004/041979, WO 2007/006305, WO 2011/036263,

WO 2011/036264, and WO 2011/072099. Suitable examples comprise especially protease variants of subtilisin protease derived from SEQ I D NO:22 as described in EP 1921147 (with amino acid substitutions in one or more of the following positions: 3, 4, 9, 15, 24, 27, 33, 36, 57, 68, 76, 77, 87, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 106, 118, 120, 123, 128, 129,

130, 131, 154, 160, 167, 170, 194, 195, 199, 205, 206, 217, 218, 222, 224, 232, 235, 236, 245, 248, 252 and 274 which have proteolytic activity. In addition, a subtilisin protease is not mu tated at positions Asp32, His64 and Ser221.

At least one subtilisin may have SEQ I D NO:22 as described in EP 1921147, or is a variant thereof which is at least 80%, at least 90%, at least 95% or at least 98% identical SEQ I D NO:22 as described in EP 1921147 and has proteolytic activity. In one embodiment, a subtil isin is at least 80%, at least 90%, at least 95% or at least 98% identical to SEQ I D NO:22 as described in EP 1921147 and is characterized by having amino acid glutamic acid (E), or as partic acid (D), or asparagine (N), or glutamine (Q), or alanine (A), or glycine (G), or serine (S) at position 101 (according to BPN’ numbering) and has proteolytic activity. In one em bodiment, subtilisin is at least 80%, at least 90%, at least 95% or at least 98% identical to SEQ I D NO:22 as described in EP 1921147 and is characterized by having amino acid glu tamic acid (E) or aspartic acid (D) , preferably glutamic acid (E), at position 101 (according to BPN’ nu mbering) and has proteolytic activity. Such a su btilisin variant may com prise an amino acid substitution at position 101, such as R101 E or R101 D, alone or in combination with one or more su bstitutions at positions 3, 4, 9, 15, 24, 27, 33, 36, 57, 68, 76, 77, 87, 95,

96, 97, 98, 99, 100, 101, 102, 103, 104, 106, 118, 120, 123, 128, 129, 130, 131, 154, 160, 167, 170, 194, 195, 199, 205, 206, 217, 218, 222, 224, 232, 235, 236, 245, 248, 252 and/or 274 (ac cording to BPN’ num bering) and has proteolytic activity. I n a preferred em bodiment, the su btilisin protease is identical to SEQ I D NO:22 as described in EP 1921147 except that the protease is characterized by having amino acid glutamic acid (E) at position 101 (according to BPN’ nu mbering) . I n one embodiment, said protease com prises one or more fu rther sub stitutions: (a) threonine at position 3 (3T) , (b) isoleucine at position 4 (41) , (c) alanine, th re onine or arginine at position 63 (63A, 63T, or 63R) , (d) aspartic acid or glutamic acid at posi tion 156 (156D or 156E) , (e) proline at position 194 (194P), (f) methionine at position 199 (199M) , (g) isoleucine at position 205 (2051) , (h) aspartic acid, glutamic acid or glycine at position 217 (217D, 217E or 217G), (i) combinations of two or more amino acids according to (a) to (h) .

A suitable su btilisin may be at least 80% identical to SEQ I D NO:22 as described in EP 1921147 and is characterized by com prising one amino acid (according to (a) -(h)) or combi nations according to (i) together with the amino acid 101E, 101D, 101 N, 101Q, 101A, 101G, or 101S (according to BPN’ nu mbering) and has proteolytic activity.

I n one embodiment, a subtilisin is at least 80% identical to SEQ I D NO:22 as described in EP 1921147 and is characterized by comprising the mutation (according to BPN’ nu mbering) R101E, or S3T + V4I + V205I, or S3T + V4I + R101 E + V205I or S3T + V4I + V199M + V205I + L217D, and has proteolytic activity. If secretion of these proteases into the fermentation medium is desired the use of the signal peptide of the AprE protein from Bacil lus subtilis is preferred.

I n another embodiment, the su btilisin com prises an amino acid sequence having at least 80% identity to SEQ I D NO:22 as described in EP 1921147 and being fu rther characterized by comprising S3T + V4I + S9R + A15T + V68A + D99S + R101S + A103S + 1104V + N218D (according to the BPN’ nu mbering) and has proteolytic activity.

A su btilisin may have an amino acid sequence being at least 80% identical to SEQ I D NO:22 as described in EP 1921147 and being fu rther characterized by comprising R101 E, and one or more substitutions selected from the group consisting of S156D, L262E, Q137H, S3T, R45E,D,Q, P55N, T58W,Y,L, Q59D,M,N,T, G61 D,R, S87E, G97S, A98D,E,R, S106A,W, N 117E, H 120V,D,K,N, S125M, P129D, E136Q, S144W, S161T, S163A,G, Y171 L, A172S, N 185Q, V199M, Y209W, M222Q, N238H, V244T, N261T,D and L262N,Q,D (as described in WO 2016/096711 and according to the BPN’ num bering), and has proteolytic activity.

I n one embodiment the subtilisin has the amino acid sequence according to SEQ I D NO:l of the present sequence listing. The subtilisin may be of animal, vegetable or microbial origin, including chemically or genet ically modified mutants (protein engineered variants). Examples of subtilisins are those de rived from Bacillus, e.g. subtilisin Novo, subtilisin Carlsberg, subtilisin BPN', subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279) and Protease PD138 (WO 93/18140). Further examples of subtilisins are described in WO 98/020115, WO 01/44452, WO 01/58275, WO 01/58276, WO 03/006602 and WO 04/099401. Other examples of subtil isins are the variants described in WO 92/19729, WO 98/20115, WO 98/20116, WO

98/34946, WO 2011/036263 and mixtures of proteases.

Examples of commercially available subtilisins include Kannase™, Everlase™, Relase™, Es- perase™, Alcalase™, Durazym™, Savinase™, Ovozyme™, Liquanase™, Coronase™, Po- larzyme™, Pyrase™, Pancreatic Trypsin NOVO (PTN), Bio-Feed™ Pro and Clear-Lens™ Pro; Blaze (all available from Novozymes A/S, Bagsvaerd, Denmark). Other commercially availa ble subtilisins include Ronozyme™ Pro, Maxatase™, Maxacal™, Maxapem™, Opticlean™, Properase™, Purafast™, Purafect™, Purafect Ox™, Purafact Prime™, Excellase™, FN2™, FN3™ and FN4™ (available from Genencor I nternational Inc., Gist-Brocades, BASF, or DSM). Other examples are Primase™ and Duralase™. Blap R, Blap S and Blap X available from Henkel.

In another embodiment, the enzyme is a lipase. Lipases or triacylglycerol hydrolases are a class of enzymes that catalyze the hydrolysis of lipids.

Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples include lipase from Thermomyces, e.g. from T. lanuginosus (previously named Humico/a lanuginosa) as described in EP 258 068 and EP 305 216, a Pseudomonas lipase, e.g. from P. alcaligenes or P. pseudo alcaligenes (EP 218 272), P. cepacia (EP 331 376), P. stutzeri{G B 1,372,034), P. f/uorescens, Pseudomonas sp. strain SD 705 (WO 95/06720 and WO 96/27002), P. wisconsinensis (WO 96/12012), a Bacil lus lipase ,e.g. from B. subti/is (Dartois et a I . , 1993, Biochemica et Biophysica Acta, 1131: 253-360), B. stearothermophi/us (JP 64/744992 ) or B. pumilus (WO 91/16422).

Other examples are lipase variants such as those described in WO 92/05249, WO 94/01541, EP 407 225, EP 260 105, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079, WO 97/07202, WO 00/060063, WO 2007/087508 and WO 2009/109500.

Preferred commercially available lipase enzymes include Lipolase™, Lipolase Ultra™, and Lipex™; Lecitase™, Lipolex™; Lipoclean™, Lipoprime™ (Novozymes A/S). Other commer cially available lipases include Lumafast (Genencor Int Inc); Lipomax (Gist-Bro- cades/Genencor Int I nc) and Bacillus sp lipase from Solvay.

I n another embodiment, the enzyme is an amylase.

Suitable amylases ( a and/or b ) include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, a - amylases obtained from Bacillus, e.g. a special strain of Bacillus Ucheniformis, described in more detail in GB 1,296,839.

Examples of useful amylases are the variants described in WO 94/02597, WO 94/18314, WO 96/23873, and WO 97/43424, especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202,

208, 209, 243, 264, 304, 305, 391, 408, and 444.

Commercially available amylases are Stainzyme; Stainzyme Plus; Duramyl™, Termamyl™, Termamyl Ultra; Natalase, Fungamyl™ and BAN™ (Novozymes A/S), Rapidase™ and Pura- star™ (from Genencor International Inc.).

Suitable cutinases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples include cutinase from Humicola, e.g. H. in- so/ensas described in WO 96/13580.

The pectate lyase may be a wild-type enzyme derived from Bacillus, particularly B. Hcheni- formis or, B. agaradhaerens, or a variant derived of any of these, e.g. as described in US 6,124,127, WO 99/027083, WO 99/027084, WO 2002/006442, WO 2002/092741, and WO 2003/095638. Commercially available pectate lyases include XPect, Pectawash and Pectaway (Novozymes A/S).

The mannanase may be an alkaline mannanase of Family 5 or 26. It may be a wild-type from Bacillus or Humicola, particularly from B. agaradhaerens, B. Ucheniformis, B.

halodurans, B. dausii, or H. inso/ens. Suitable mannanases are described in WO 99/064619. A commercially available mannanase is Mannaway (Novozymes A/S).

Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera Ba cillus, Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium, e.g. the fungal cellulases produced from Humicola inso/ens, Myceliophthora thermophile and Fusarium oxysporum disclosed in US 4,435,307, US 5,648,263, US 5,691,178, US 5,776,757 and WO 89/09259.

Especially suitable cellulases are the alkaline or neutral cellulases having color care bene fits. Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372,

WO 96/11262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and WO 99/01544.

Commercially available cellulases are Celluzyme, Celluclean, Endolase, Carezyme, Reno- zyme, and whitezyme (Novozymes A/S) or Biotouch (AB Enzymes).

As discussed above, the present invention further relates a composition comprising a com pound according to formula (I) and an enzyme, preferably a hydrolase, more preferably a protease and most preferably a subtilisin. The composition can be provided in liquid or granular form. The composition may be added to a detergent composition, which further comprises one or more surfactants. The detergent composition may, e.g. be a laundry detergent composition or a dishwashing detergent com position.

The liquid detergent composition is in a physical form, which is not solid (or gas). It may be a pourable liquid, a pourable gel or a non-pourable gel. It may be either isotropic or struc tured, preferably it is isotropic. It includes formulations useful for washing in automatic washing machines or for hand washing. The detergent composition contains at least one surfactant. The detergent composition may also include a builder.

The particulate detergent composition may be a granulate or powder, or a powder/granulate pressed to a tablet, briquette. The detergent composition may be in the form of a tablet, bar or pouch, including multi-compartment pouches. The detergent composition can be in the form of a powder, for example a free-flowing powder, such as an agglomerate, spray-dried powder, encapsulate, extrudate, needle, noodle, flake, or any combination thereof.

Pouches can be of any form, shape and material which is suitable for holding the composi tion, e.g. without allowing the release of the composition from the pouch prior to water con tact. The pouch is made from water-soluble film, which encloses an inner volume. Said in ner volume can be divided into compartments of the pouch. Preferred films are polymeric materials preferably polymers which are formed into a film or sheet. Preferred polymers, co polymers or derivates thereof are selected polyacrylates, and water-soluble acrylate copoly mers, methyl cellulose, carboxy methyl cellulose, sodium dextrin, ethyl cellulose, hydroxy- ethyl cellulose, hydroxypropyl methyl cellulose, malto dextrin, poly methacrylates, most preferably polyvinyl alcohol copolymers and, hydroxypropyl methyl cellulose (HPMC). Pref erably, the level of polymer in the film for example PVA is at least about 60%. Preferred av erage molecular weight will typically be about 20,000 to about 150,000. Films can also be a blend compositions comprising hydrolytically degradable and water-soluble polymer blends such as polyactide and polyvinyl alcohol (known under the Trade reference M8630 as sold by Chris Craft In. Prod. Of Gary, I nd ., US) plus plasticizers like glycerol, ethylene glycerol, Propylene glycol, sorbitol and mixtures thereof. The pouches can comprise a solid laundry cleaning composition or part components and/or a liquid cleaning composition or part com ponents separated by the water-soluble film. The compartment for liquid components can be different in composition from compartments containing solids (see e.g. US

2009/0011970).

In one embodiment, the composition according to the present invention may be added to a detergent composition in an amount corresponding to 0.001-100 mg of protein, such as 0.01-100 mg of protein, preferably 0.005-50 mg of protein, more preferably 0.01-25 mg of protein, even more preferably 0.05-10 mg of protein, most preferably 0.05-5 mg of protein, and even most preferably 0.01-1 mg of protein per liter of detergent composition.

In a composition such as a liquid or granular detergent, the amount of each enzyme (e.g. subtilisin and optionally a second or more enzymes) will typically be 0.04-80 mM (or pmol/kg), in particular 0.2-30 mM, especially 0.4-20 mM (generally 1-2000 mg/I or mg/kg, in particular 5-750 mg/I, especially 10-500 mg/I) calculated as pure enzyme protein. In a com position such as an enzyme concentrate the amount of each enzyme will typically be 0.01- 20 mM, in particular 0.04-10 mM, especially 0.1-5 mM (generally 0.3-500 g/l, in particular 1- 300 g/l, especially 3-150 g/l) calculated as pure enzyme protein.

The molar ratio of a compound according to formula (I) to the enzyme (e.g. subtilisin) is at least 1:1 or 1.5:1, and it is less than 1000:1, more preferred less than 500:1, even more pre ferred from 100:1 to 2:1 or from 20:1 to 2:1, or most preferred, the molar ratio is from 10:1 to 2:1.

In one embodiment, the composition comprises at least one further enzyme which is also called the second enzyme. In a preferred embodiment, the at least one further enzyme is selected from a lipase, protease, cutinase, amylase, carbohydrase, cellulase, pectinase, pectate lyase, mannanase, arabinase, galactanase, xylanase, oxidase, laccase, peroxidase and combinations thereof. Preferably, the second enzyme is an enzyme as described herein. The composition may contain one or more additional proteases, if the first enzyme is a pro tease. The composition may contain one, two or more non-subtilisin enzymes. The composi tion may contain one or more additional subtilisins, if the first enzyme is a subtilisin.

As described above, the detergent composition may comprise one or more surfactants, which may be anionic and/or cationic and/or non-ionic and/or semi-polar and/or zwitteri- onic, or a mixture thereof. In one embodiment, the detergent composition includes a mixture of one or more non-ionic surfactants and one or more anionic surfactants.

The surfactant(s) is typically present from about 0.1% to 60% by weight, such as from about 1% to about 40%, or from about 3% to about 20%, or from about 3% to about 10%. The sur factants) is chosen based on the desired cleaning application, and includes any conven tional surfactant(s) known in the art. Any surfactant known in the art for use in detergents may be utilized.

Examples of anionic surfactants include sulfates and sulfonates, in particular, linear al- kylbenzenesulfonates (LAS), isomers of LAS, branched alkylbenzenesulfonates (BABS), phenylalkanesulfonates, alpha-olefinsulfonates (AOS), olefin sulfonates, alkene sulfonates, alkane-2, 3-diylbis(sulfates), hydroxyalkanesulfonates and disulfonates, alkyl sulfates (AS) such as sodium dodecyl sulfate (SDS), fatty alcohol sulfates (LAS), primary alcohol sulfates (PAS), alcohol ethersulfates (AES or AEOS or EES, also known as alcohol ethoxysulfates or fatty alcohol ether sulfates, including sodium lauryl ether sulfate (SLES), soaps or fatty ac ids; secondary alkanesulfonates (SAS), paraffin sulfonates (PS), ester sulfonates, sul- fonated fatty acid glycerol esters, alpha-sulfo fatty acid methyl esters (alpha-SFMe or SES) including methyl ester sulfonate (MES), alkyl- or alkenylsuccinic acid, dodecenyl/tetrade- cenyl succinic acid (DTSA), fatty acid derivatives of amino acids, diesters and monoesters of sulfo-succinic acid or soap, and combinations thereof.

When included therein the detergent composition will usually contain from about 1% to about 40% by weight, such as from about 5% to about 30%, including from about 5% to about 15%, or from about 20% to about 25% of an anionic surfactant. Exam ples of non-ionic su rfactants include alcohol ethoxylates (AE or AEO) , alcohol propox- ylates, propoxylated fatty alcohols (PFA) , al koxylated fatty acid al kyl esters, such as ethox- ylated and/or propoxylated fatty acid al kyl esters, al kyl phenol ethoxylates (APE), nonyl phe- nol ethoxylates (N PE), al kyl polyglycosides (APG) , al koxylated amines, fatty acid monoeth- anolamides (FAM) , fatty acid diethanolamides (FADA) , ethoxylated fatty acid monoethano- lamides (EFAM), propoxylated fatty acid monoethanolamide (PFAM), polyhyd roxy al kyl fatty acid amides, or N-acyl N-al kyl derivatives of glucosamine (glucamides, GA, or fatty acid glu- camide, FAGA) , as wel l as products available under the trade names SPAN and TWEEN, and com binations thereof.

When included therein the detergent com position wil l usual ly contain from about 0.2% to about 40% by weight of a non-ionic su rfactant, for example from about 0.5% to about 30%, in particu lar from about 1% to about 20%, from about 3% to about 10%, such as from about 3% to about 5%, or from about 8% to about 12%.

The detergent com position may contain about 0-65% by weight of a builder or co-builder, or a mixture thereof. I n a dish wash detergent, the level of builder is typical ly 40-65%, particu larly 50-65%. The builder and/or co-builder may particu larly be a chelating agent that forms water-solu ble com plexes with Ca and Mg. Any builder and/or co-builder known in the art for use in lau ndry detergents may be utilized. Exam ples of builders that can be included are in particu lar silicates, aluminu m silicates (in particu lar zeolites) , carbonates, salts of organic di- and polycarboxylic acids and mixtu res of these su bstances. Non-limiting exam ples of builders include zeolites, diphosphates (pyrophosphates), triphosphates such as sodiu m tri phosphate (STP or STPP) , nitrilotriacetic acid, ethylenediaminetetraacetic acid (EDTA), di- ethylenetriaminepentaacetic acid, al kyl- or al kenylsuccinic acid, carbonates such as sodium carbonate, solu ble silicates such as sodiu m metasilicate, layered silicates (e.g., SKS-6 from Hoechst) , ethanolamines such as 2-aminoethan-l-ol (M EA) , iminodiethanol (DEA) and 2,2',2"-nitrilotriethanol (TEA) , and carboxymethylinulin (CM I), and com binations thereof.

The builder may be a strong builder such as methyl glycine diacetic acid ("MGDA") or N_rN- Dicarboxymethyl glutamic acid tetrasodiu m salt (G LDA) ; it may be a mediu m builder such as sodiu m tri-poly-phosphate (STPP), or it may be a weak builder such as sodiu m citrate.

Organic builders that can be present in the detergent com position are for example the poly carboxylic acids that can be used in the form of their sodiu m salts, polycarboxylic acids be ing u nderstood to be carboxylic acids bearing more than one acid function. These are for example citric acid, adipic acid, succinic acid, glutaric acid, malic acid, tartaric acid, maleic acid, fumaric acid, sugar acids, aminocarboxylic acids, nitrilotriacetic acid (NTA), methyl gly cine diacetic acid (MGDA) and derivatives and mixtures thereof. Preferred salts are the salts of polycarboxylic acids such as citric acid, adipic acid, succinic acid, glutaric acid, tar taric acid, sugar acids and mixtures thereof.

Polymeric polycarboxylates are also suitable as builders. These are for example the al kali metal salts of polyacrylic acid or polymethacrylic acid, for exam ple those having a relative molar mass of 600 to 750,000 g/mol. Suitable polymers are in particu lar polyacrylates, which preferably have a molar mass of 1000 to 15,000 g/mol. Of this group, owing to their su perior solu bility, preference can in tu rn be given to the short-chain polyacrylates having molar masses of 1000 to 10,000 g/mol and particu larly preferably of 1000 to 5000 g/mol.

Also suitable are copolymeric polycarboxylates, in particular those of acrylic acid with meth- acrylic acid and of acrylic acid or methacrylic acid with maleic acid. To improve their solubil ity the polymers can also contain al lyl sulfonic acids, such as al lyloxybenzenesu lfonic acid and methal lyl su lfonic acid, as monomers.

However, soluble builders, such as for example citric acid, or acrylic polymers having a mo lar mass of 1000 to 5000 g/mol are preferably used.

Within the meaning of this application the molar masses specified for the polymeric poly carboxylates are weight-average molar masses M_w of the individual acid form, which were determined in principle by gel permeation ch romatography (GPC) using a UV detector. The measu rement was carried out against an external polyacrylic acid standard, which because of its structural affinity to the polymers u nder investigation delivers realistic molar mass val ues. These figu res differ markedly from the molar mass values obtained using polystyrene su lfonic acids as the standard. The molar masses measured against polystyrene sulfonic acids are general ly significantly higher than the molar masses given in this pu blication.

Such organic builder su bstances can be included if desired in amou nts of up to 40 wt.-%, in particu lar u p to 25 wt.-% and preferably from 1 wt.-% to 8 wt.-%. Amounts close to the cited u pper limit are preferably used in paste-form or liquid, in particu lar water-containing, deter gent com positions.

I n the case that the com positions according to the invention are provided in liquid form, they contain preferably water as the main solvent. Non-aqueous solvents can also or addi tional ly be used. Suitable non-aqueous solvents encom pass mono- or polyhydric alcohols, al kanolamines or glycol ethers, provided they are miscible with water in the specified con centration range. The solvents are preferably selected from ethanol, n-propanol, iso-propa- nol, butanols, glycol, propanediol, butanediol, glycerol, diglycol, propyl diglycol, butyl di glycol, hexylene glycol, ethylene glycol methyl ether, ethylene glycol ethyl ether, ethylene glycol propyl ether, ethylene glycol mono-n-butyl ether, diethylene glycol methyl ether, di ethylene glycol ethyl ether, propylene glycol methyl ether, propylene glycol ethyl ether, pro pylene glycol propyl ether, dipropylene glycol monomethyl ether, dipropylene glycol mo noethyl ether, diisopropylene glycol monomethyl ether, diisopropylene glycol monoethyl ether, methoxytriglycol, ethoxytriglycol, butoxytriglycol, l-butoxyethoxy-2-propanol, 3-me- thyl-3-methoxybutanol, propylene glycol t-butyl ether, di-n-octyl ether and mixtu res of these solvents. It is however preferable for the com position to contain a polyol as the non- aqueous solvent. The polyol can in particu lar encom pass glycerol, 1,2-propanediol, 1,3-pro- panediol, ethylene glycol, diethylene glycol and/or dipropylene glycol. The com position pref erably contains in particu lar a mixture of a polyol and a monohydric alcohol. Non-aqueous solvents can be used in amounts of between 0.5 and 15 wt.-%, but preferably below 12 wt.-

%.

To set a desired pH that is not established automatically by mixing the other components, the composition can contain system-compatible and environmentally compatible acids, in particular citric acid, acetic acid, tartaric acid, malic acid, lactic acid, glycolic acid, succinic acid, glutaric acid and/or adipic acid, but also mineral acids, in particular sulfuric acid, or bases, in particular ammonium or alkali hydroxides. Such pH regulators are included in the agents in amounts preferably not exceeding 20 wt.-%, in particular from 1.2 wt.-% to 17 wt.- %.

A composition according to the invention can furthermore contain one or more water-solu ble salts, which serve the purpose of viscosity adjustment for example. They can be inor ganic and/or organic salts. Inorganic salts that can be used are preferably selected from the group comprising colorless water-soluble halides, sulfates, sulfites, carbonates, hydrogen carbonates, nitrates, nitrites, phosphates and/or oxides of alkali metals, alkaline-earth met als, aluminum and/or transition metals; ammonium salts can also be used. Halides and sul fates of alkali metals are particularly preferred; the inorganic salt is therefore preferably se lected from the group comprising sodium chloride, potassium chloride, sodium sulfate, po tassium sulfate and mixtures thereof. Organic salts that can be used are for example color less water-soluble alkali metal, alkaline-earth metal, ammonium, aluminum and/or transi tion metal salts of carboxylic acids. The salts are preferably selected from the group com prising formate, acetate, propionate, citrate, malate, tartrate, succinate, malonate, oxalate, lactate and mixtures thereof.

The composition can contain one or more thickening agents for thickening purposes. The thickening agent is preferably selected from the group comprising xanthan gum, guar gum, carrageenan, agar agar, ge Man, pectin, carob seed meal and mixtures thereof. These com pounds are effective thickening agents even in the presence of inorganic salts. The thicken ing agent additionally stabilizes the continuous, low-surfactant phase and prevents a mac roscopic phase separation.

The composition may comprise further enzyme inhibitors or stabilizers. Examples of such enzyme inhibitors or stabilizers are boric acid and boronic acids. Examples of boronic acids are alkyl boronic acids such as methylboronic acid, butylboronic acid, and 2-cyclohexylethyl- boronic acid; and aryl boronic acids such as phenylboronic acid, 4-methoxyphenylboronic acid, 3,5-dichlorophenylboronic acid, and 4-formylphenylboronic acid (4-FPBA).

The present invention is further directed to a method of preparing the composition accord ing to the invention.

In one embodiment, the method comprises the step of mixing the enzyme, preferably prote ase, the compound of formula (I) and optionally one or more surfactants.

The present invention is further directed to a cleaning agent comprising the compound ac cording to formula (I) or the composition according to the invention. The present invention is further directed to a method of preparing a compound of formula (I) or a salt thereof. The method comprises the following steps:

a) providing a compound according to formula

N

R³

4

b) converting the compound of step a) to R or the corresponding salt thereof

having the formula

d) optionally, converting the compound obtained in step

in the compound of step c) is not hydrogen;

R¹

^Z N^T^OH

e) reacting the compound obtained in step c) or d) with ^H & to obtain a corn

pound according to formula

salt thereof.

X is selected from F, Cl, Br and I and R¹ to R⁵ and Z are defined as hereinabove.

The following examples are provided for illustrative purposes. It is thus understood that the examples are not to be construed as limiting. The skilled person will clearly be able to en visage further modifications of the principles laid out herein. EXAMPLES

A. Synthesis Examples

Example 1: Preparation of Z-Val-Ala-Ala-(OMe)₂

To a solution of 50 ml (49 g, 0.46 mol) benzylamine in 250 ml heptane in a 20° C water bath was added 64.5 ml (63 g, 0.53 mol) pyruvic aldehyde dimethylacetal. Temperature rose to -30° C. 20 g anhydrous MgS0₄ was added and the suspension was allowed to stir for 16 h at 20° C. The suspension was concentrated before the unreacted starting materials were removed under high vacuum at 35° C. 81.6 g (86%) of a colorless oil was obtained. Ή NMR (CDCI₃) 7.22-7.38 (m, 5), 4.573 (br s, 2), 4.567 (s, 1), 3.45 (s, 6) and 1.55 (s, 3) ppm.

81.6 g (0.39 mol) of the above compound was dissolved in 430 ml methanol and cooled to 5° C in an ice-salt bath. 17.04 g NaBH₄ (0.45 mol) was added to the clear solution in ~15 portions. The first 5 portions caused a rise in temperature to 10-12° C and much H₂ evolved. The resulting suspension was allowed to stir overnight and warm to RT. The light yellow solution formed was concentrated in vacuo. 150 ml toluene and 200 ml water were added to the residue. The organic phase was separated and aqueous phase extracted with 100 ml toluene. The combined organic phases were dried over MgS0₄ and concentrated in vacuo to give 77.5 g (94%) of a pale yellow oil. Ή NMR (CDCI₃) 7.43-7.17 (m, 5), 4.17 (d, 1), 3.82 (dd, 2), 3.41 (s, 3), 3.38 (s, 3), 2.86 (pentet, 1), 1.76 (br s, 1), and 1.13 (d, 3) ppm.

76.7 g (0.37 mol) of the above compound was hydrogenated in 430 ml methanol with 7.5 g 10% Pd/C and 3 bar H₂ for 26 h. The solution was then filtered and concentrated and dis solved in 300 ml ether. The ethereal solution was cooled to 4° C and 11.0 g gaseous HCI were introduced over 1.5 h. At the end of the addition, the suspension was allowed to warm to RT and stir for 3 h. The suspension was filtered, washed with 2x50 ml ether, then dried under high vacuum to afford 42.5 g (0.27 mol, 74%) of a white solid. Ή NM R (D₂0) 4.70 (br s, 3), 4.46 (d, 1), 3.49 (s, 3), 3.46 (s, 3), 3.44 (dq, 1), and 1.25 (d, 3) ppm.

d)

To a suspension of 7.68 g (49 mmol) of the above compound in 100 ml ethyl acetate in a water bath at RT was added 26.6 ml (19.4 g, 150 mmol) diisopropylethylamine via syringe. Temperature decreased slightly and the suspension became lighter. 11.67 g (52 mmol) Z- Ala-OH was added as a solid followed by 35.2 ml 50% (59 mmol) propylphosphonic acid an hydride (PPAA) over 30 min by means of a syringe pump. Temperature decreased slightly. The resulting pale yellow suspension was allowed to stir at RT for 5 h. The Reaction mix ture was poured into 100 ml sat’d NaHC0₃. Organic phase was separated and washed with 50 ml water, 50 ml brine, then dried over MgS0₄ and concentrated in vacuo to give 14.85 g (93%) of an off-white solid. Ή NMR (CDCI₃) 7.42-7.30 (m, 5), 6.19 (br s, 1), 5.49 (br s, 1), 5.12 (br s, 2), 4.30-4.08 (m, 3), 3.45-3.36 (4s, 6), 1.39 (d, 3) and 1.12 (br d, 3) ppm.

14.0 g (43 mmol) of the above compound was hydrogenated in 140 ml methanol with 1.5 g 10% Pd/C and 3 bar H₂ for 17 h. The solution was then filtered and concentrated in vacuo to provide 7.63 g (64 mmol, 93%) of pale yellow oil. Ή NMR (CDCI₃) 7.34 (m, 1), 4.24-4.07 (m, 2), 3.49 (dq, 1), 3.45-3.42 (4s, 6), 1.50 (br s, 2), 1.34 (dd, 3), and 1.14 (dd, 3) ppm.

f)

To a solution of 4.06 g (21.3 mmol) of the above compound in 75 ml methyl- Abutylether at RT was added 7.6 ml (5.65 g, 44 mmol) diisopropylethylamine via syringe. Temperature de creased slightly and the suspension became lighter. 5.68 g (22.6 mmol) Z-Val-OH was added as a solid followed by 15.3 ml 50% (26 mmol) propylphosphonic acid anhydride (PPAA) over 40 min by means of a syringe pump. The resulting suspension was allowed to stir overnight at RT. The suspension was treated with 100 ml sat’d NaHC0₃ and filtered washing the solid with water and methyl- Abutylether. Drying under high vacuum gave 7.65 g (85%) of a fluffy white solid. Ή NMR (CDCI₃) 7.47-7.29 (m, 5), 6.58 (br s, 1), 6.22 (br s, 1), 5.14 (m, 2), 4.48 (pentet, 1), 4.24-4.10 (m, 2), 4.05 (br t, 1), 3.46-3.38 (4s, 6), 2.14 (septet, 1), 1.39 (d, 3), 1.18-1.08 (m, 3) and 1.03-0.87 (3d, 6) ppm.

Example 2: Preparation of Z-Val-Ala-Leu-(OMe)₂

Z-V al -AI a-Leu -{OMe )₂ Z-Val-Ala-Leu-(OMe)₂ was obtained via steps analogous to steps a) to f) of Example 1.

Example 3: Preparation of Z-Val-Ala-Leu-(OEt)₂

Z-Val-Ala-Leu-(OEt)₂ was obtained via steps analogous to steps a) to f) of Example 1.

Example 4: Preparation of Z-Val-Ala-Nva-(OEt)₂

Z-Val-Ala-Nva-(OEt)₂ was obtained via steps analogous to steps a) to f) of Example 1.

Example 5: Preparation of Z-Val-Ala-Phe-(OMe)₂

Z-Val-Ala-Phe-(OMe)₂ was obtained via steps analogous to steps a) to f) of Example 1.

Example 6: Preparation of Z-Val-Ala-Nva-(0-iPr)₂

Z-ValrAla-Nva-{0-/Pr)₂ A mixture of 6.77 g (15 mmol) Cbz-Val-Ala-Nva-(OEt)₂ from Example 6 above and 0.38 g (1.5 mmol) pyridinium tosylate in 60 ml isopropanol was heated under reflux overnight. After cooling, the thick suspension was filtered, the solid washed with 20 ml cold isopropanol. Recrystallization of the solid in isopropanol gave 1.06 (14%) of a white solid. Ή NMR (CDCI₃) 7.45-7.30 (m, 5), 6.65-6.39 (m, 1), 6.02-5.79 (m, 1), 5.43-5.26 (br d, 1), 5.14 (m, 2), 4.56-4.38 (m, 2), 4.12-3.92 (m, 2), 3.92-3.39 (m, 2), 2.13 (septet, 1) and 1.72-0.84 (multiple m, 28) ppm.

Example 7: Preparation of Z-Val-Ala-Leu-(0-iPr)₂

Z-Val-Ala-Leu-(0-iPr)₂ was obtained analogous to Example 6.

Example 8: Preparation of Z-Val-Ala-Leu-(0-iBu)₂

Z-Val-Ala-Leu-(0-iBu)₂ was obtained was obtained analogous to Example 6.

Example 9: Preparation of Z-Val-Ala-Phe-(0-/Pr)₂

Z-Val-Ala-Phe-(0-/Pr)₂ was obtained analogous to Example 6.

Example 10: Preparation of Z-Val-Ala-Leu-(0-3-pentyl)₂

Z-Val-Ala-Leu-(0-3-pentyl)₂ was obtained analogous to Example 6.

Example 11: Preparation of Z-Val-Ala-Phe-(0-neopentyl)₂

Z-Val-Ala-Phe-(0-neopentyl)₂ was obtained was obtained analogous to Example 6.

B. Storage and Proteases Stability

To assess the ability of synthesized peptides to stabilize a protease storage trials were per formed using a subtilisin according to SEQ I D NO:l being the BLAP WT and being charac- terized by comprising the mutation (according to BPN’ numbering) R101E.

For the storage trials compositions as depicted in Table 1 with the ingredients given in w/w were prepared:

The compositions were stored at a temperature of 30° for 31, 60 and 119 days and the re sidual protease activity after storage was analyzed by measuring the reactivity towards the peptidic substrate Suc-AAPF-pNA. Here pNA is cleaved from the substrate molecule at 30° C, pH 8.6 using lOOmM TRIS buffer. The rate of cleavage, directly proportional to the protease activity, can be determined by the increase of the yellow color of free pNA in the solution by measuring OD₄₀₅, the optical density at 405 nm.

In Table 2 the residual activity is given referenced to the initial value. It can be seen that the stabilizer according to the invention (Formulations 1 and 2) is superior over its reference molecule tested in formulations 3 and 4 under the two different pH conditions, i.e., pH 4.5 and pH 5.5.

Claims

1. Compound of formula (I) or a salt thereof

wherein

R¹, R² and R³are each independently selected from the group consisting of hydrogen, optionally substituted C^alkyl, optionally substituted C_2-6 alkenyl, optionally substi tuted C_j^alkoxy, optionally substituted 3- to 12-membered cycloalkyl, and optionally substituted 6- to 10-membered aryl; or wherein each R¹, R² and R³ is independently selected as -(CH₂)₃- which is also attached to the nitrogen atom of -NH-C(H)- so that -N-C(H)R^1,2or3- forms a 5-membered heterocyclic ring;

R⁴and R⁵ are each independently selected from the group consisting of hydrogen, op tionally substituted C^alkyl, optionally substituted C_2-6 alkenyl, optionally substituted C_j^alkoxy, optionally substituted C^acyl, optionally substituted C^alkyl phenyl, and optionally substituted 6- to 10-membered aryl; or wherein R⁴and R⁵ are joined to form an optionally substituted 5- to 12-membered ring;

2. Compound according to claim 1, wherein R¹ and R² is a group such that NH-CHR^CO and NH-CHR²-CO is an L or D-amino acid residue of Gly, Ala, Val, Leu, lie, Met, Pro, Phe, Trp, Ser, Thr, Asp, Gin, Tyr, Cys, Lys, Arg, His, Asn, Glu, m-tyrosine, 3,4-dihydrox- yphenylalanine, Nva, or Nle.

3. Compound according to claim 1 or 2, wherein R³ is a group such that NH-CHR³-CO is an L or D-amino acid residue of Gly, Ala, Val, Leu, lie, Met, Pro, Phe, Trp, Ser, Thr,

Asp, Gin, Tyr, Cys, Lys, Arg, His, Asn, Glu, m-tyrosine, 3,4-dihydroxyphenylalanine,

Nva, or Nle, or wherein R³ is (CH₃)₃SiCH₂.

4. Compound according to any one of claims 1 to 3, wherein R¹ is a group such that NH- CHR^CO is an L or D-amino acid residue of Ala, Val, Gly, Arg, Leu, Phe or Thr.

5. Compound according to any one of claims 1 to 4, wherein R² is a group such that NH- CHR²-CO is an L or D-amino acid residue of Ala, Cys, Gly, Pro, Ser, Thr, Val, Nva or Nle.

6. Compound according to any one of claims 1 to 5, wherein R³ is a group such that NH- CHR³-CO is an L or D-amino acid residue of Tyr, m-tyrosine, 3,4-dihydroxyphenylala- nine, Phe, Val, Ala, Met, Nva, Leu, lie or Nle.

7. Compound according to any one of claims 1 to 6, wherein R⁴ and R⁵ are each inde

pendently selected from methyl (Me), ethyl (Et), isopropyl (/Pr) or isobutyl (/Bu), pref erably from methyl or ethyl.

8. Compound according to any one of claims 1 to 7, wherein R⁴ and R⁵ are both methyl, ethyl, or isopropyl.

9. Compound according to any one of claims 1 to 8, wherein Z is an N-terminal protec tion group.

10. Compound according to claim 9, wherein the N-terminal protection group is selected from benzyloxycarbonyl (Cbz), p-methoxybenzyl carbonyl (MOZ), benzyl (Bn), benzoyl (Bz), p-methoxybenzyl (PMB), p-methoxyphenyl (PMP), formyl, acetyl (Ac), methyloxy, alkoxycarbonyl, methoxycarbonyl (Moc), fluorenylmethyloxycarbonyl (Fmoc) or tert- butyloxycarbonyl (t-Boc).

11. Compound according to any one of claims 1 to 10, which is selected from

Cbz-Gly-Ala-Tyr-(OMe)₂,

Cbz-Gly-Ala-Tyr-(OEt)₂,

Ac-Gly-Ala-Tyr-(OMe)₂,

Ac-Gly-Ala-Tyr-(OEt)₂,

Cbz-Gly-Ala-Tyr-(0/Pr)₂,

Cbz-Gly-Ala-Tyr-(0/Bu)₂,

Ac-Gly-Ala-Tyr-(0/Pr)₂,

Ac-Gly-Ala-Tyr-(0/Bu)₂,

Bz-Gly-Ala-Tyr-(OMe)₂,

Bz-Gly-Ala-Tyr-(OEt)₂,

Fmoc-Gly-Ala-Tyr-(OMe)₂,

Fmoc-Gly-Ala-Tyr-(OEt)₂,

Bz-Gly-Ala-Tyr-(0/Pr)₂,

Bz-Gly-Ala-Tyr-(0/Bu)₂,

Fmoc-Gly-Ala-Tyr-(0/Pr)₂,

Fmoc-Gly-Ala-Tyr-(0/Bu)₂,

Cbz-Gly-Ala-Leu-(OMe)₂,

Cbz-Gly-Ala-Leu-(OEt)₂,

Ac-Gly-Ala-Leu-(OMe)₂,

Ac-Gly-Ala-Leu-(OEt)₂,

Cbz-Gly-Ala-Leu-(0/Pr)₂,

Cbz-Gly-Ala-Leu-(0/Bu)₂,

Ac-Gly-Ala-Leu-(0/Pr)₂, Ac-Gly-Ala-Leu-(0/Bu)₂,

Bz-Gly-Ala-Leu-(OMe)₂,

Bz-Gly-Ala-Leu-(OEt)₂,

Fmoc-Gly-Ala-Leu-(OMe)₂,

Fmoc-Gly-Ala-Leu-(OEt)₂,

Bz-Gly-Ala-Leu-(0/Pr)₂,

Bz-Gly-Ala-Leu-(0/Bu)₂,

Fmoc-Gly-Ala-Leu-(0/Pr)₂,

Fmoc-Gly-Ala-Leu-(0/Bu)₂,

Cbz-Val-Ala-Leu-(OMe)₂,

Cbz-Val-Ala-Leu-(OEt)₂,

Ac-Val-Ala-Leu-(OMe)₂,

Ac-Val-Ala-Leu-(OEt)₂,

Cbz-Val-Ala-Leu-(0/Pr)₂,

Cbz-Val-Ala-Leu-(0/Bu)₂,

Ac-Val-Ala-Leu-(0/Pr)₂,

Ac-Val-Ala-Leu-(0/Bu)₂,

Bz-Val-Ala-Leu-(OMe)₂,

Bz-Val-Ala-Leu-(OEt)₂,

Fmoc-Val-Ala-Leu-(OMe)₂,

Fmoc-Val-Ala-Leu-(OEt)₂,

Bz-Val-Ala-Leu-(0/Pr)₂,

Bz-Val-Ala-Leu-(0/Bu)₂,

Fmoc-Val-Ala-Leu-(0/Pr)₂,

Fmoc-Val-Ala-Leu-(0/Bu)₂,

Cbz-Val-Ala-Ala-(OMe)₂,

Cbz-Val-Ala-Ala-(OEt)₂,

Ac-Val-Ala-Ala-(OMe)₂,

Ac-Val-Ala-Ala-(OEt)₂,

Cbz-Val-Ala-Ala-(0/Pr)₂,

Cbz-Val-Ala-Ala-(0/Bu)₂,

Ac-Val-Ala-Ala-(0/Pr)₂,

Ac-Val-Ala-Ala-(0/Bu)₂,

Bz-Val-Ala-Ala-(OMe)₂,

Bz-Val-Ala-Ala-(OEt)₂,

Fmoc-Val-Ala-Ala-(OMe)₂,

Fmoc-Val-Ala-Ala-(OEt)₂,

Bz-Val-Ala-Ala-(0/Pr)₂,

Bz-Val-Ala-Ala-(0/Bu)₂,

Fmoc-Val-Ala-Ala-(0/Pr)₂,

Fmoc-Val-Ala-Ala-(0/Bu)₂,

Cbz-Arg-Ala-Tyr-(OMe)₂, Cbz-Arg-Ala-Tyr-(OEt)₂,

Ac-Arg-Ala-Tyr-(OMe)₂,

Ac-Arg-Ala-Tyr-(OEt)₂,

Cbz-Arg-Ala-Tyr-(0/Pr)₂,

Cbz-Arg-Ala-Tyr-(0/Bu)₂,

Ac-Arg-Ala-Tyr-(0/Pr)₂,

Ac-Arg-Ala-Tyr-(0/Bu)₂,

Bz-Arg-Ala-Tyr-(OMe)₂,

Bz-Arg-Ala-Tyr-(OEt)₂,

Fmoc-Arg-Ala-Tyr-(OMe)₂,

Fmoc-Arg-Ala-Tyr-(OEt)₂,

Bz-Arg-Ala-Tyr-(0/Pr)₂,

Bz-Arg-Ala-Tyr-(0/Bu)₂,

Fmoc-Arg-Ala-Tyr-(0/Pr)₂,

Fmoc-Arg-Ala-Tyr-(0/Bu)₂,

Cbz-Gly-Ala-Phe-(OMe)₂,

Cbz-Gly-Ala-Phe-(OEt)₂,

Ac-Gly-Ala-Phe-(OMe)₂,

Ac-Gly-Ala-Phe-(OEt)₂,

Cbz-Gly-Ala-Phe-(0/Pr)₂,

Cbz-Gly-Ala-Phe-(0/Bu)₂,

Ac-Gly-Ala-Phe-(0/Pr)₂,

Ac-Gly-Ala-Phe-(0/Bu)₂,

Bz-Gly-Ala-Phe-(OMe)₂,

Bz-Gly-Ala-Phe-(OEt)₂,

Fmoc-Gly-Ala-Phe-(OMe)₂,

Fmoc-Gly-Ala-Phe-(OEt)₂,

Bz-Gly-Ala-Phe-(0/Pr)₂,

Bz-Gly-Ala-Phe-(0/Bu)₂,

Fmoc-Gly-Ala-Phe-(0/Pr)₂,

Fmoc-Gly-Ala-Phe-(0/Bu)₂,

Cbz-Gly-Ala-Val-(OMe)₂,

Cbz-Gly-Ala-Val-(OEt)₂,

Ac-Gly-Ala-Val-(OMe)₂,

Ac-Gly-Ala-Val-(OEt)₂,

Cbz-Gly-Ala-Val-(0/Pr)₂,

Cbz-Gly-Ala-Val-(0/Bu)₂,

Ac-Gly-Ala-Val-(0/Pr)₂,

Ac-Gly-Ala-Val-(0/Bu)₂,

Bz-Gly-Ala-Val-(OMe)₂,

Bz-Gly-Ala-Val-(OEt)₂,

Fmoc-Gly-Ala-Val-(OMe)₂,

Fmoc-Gly-Ala-Val-(OEt)₂,

Bz-Gly-Ala-Val-(0/Pr)₂, Bz-Gly-Ala-Val-(0/Bu)₂,

Fmoc-Gly-Ala-Val-(0/Pr)₂,

Fmoc-Gly-Ala-Val-(0/Bu)₂,

Cbz-Gly-Gly-Tyr-(OMe)₂,

Cbz-Gly-Gly-Tyr-(OEt)₂,

Ac-Gly-Gly-Tyr-(OMe)₂,

Ac-Gly-Gly-Tyr-(OEt)₂,

Cbz-Gly-Gly-Tyr-(0/Pr)₂,

Cbz-Gly-Gly-Tyr-(0/Bu)₂,

Ac-Gly-Gly-Tyr-(0/Pr)₂,

Ac-Gly-Gly-Tyr-(0/Bu)₂,

Bz-Gly-Gly-Tyr-(OMe)₂,

Bz-Gly-Gly-Tyr-(OEt)₂,

Fmoc-Gly-Gly-Tyr-(OMe)₂,

Fmoc-Gly-Gly-Tyr-(OEt)₂,

Bz-Gly-Gly-Tyr-(0/Pr)₂,

Bz-Gly-Gly-Tyr-(0/Bu)₂,

Fmoc-Gly-Gly-Tyr-(0/Pr)₂,

Fmoc-Gly-Gly-Tyr-(0/Bu)₂,

Cbz-Gly-Gly-Phe-(OMe)₂,

Cbz-Gly-Gly-Phe-(OEt)₂,

Ac-Gly-Gly-Phe-(OMe)₂,

Ac-Gly-Gly-Phe-(OEt)₂,

Cbz-Gly-Gly-Phe-(0/Pr)₂,

Cbz-Gly-Gly-Phe-(0/Bu)₂,

Ac-Gly-Gly-Phe-(0/Pr)₂,

Ac-Gly-Gly-Phe-(0/Bu)₂,

Bz-Gly-Gly-Phe-(OMe)₂,

Bz-Gly-Gly-Phe-(OEt)₂,

Fmoc-Gly-Gly-Phe-(OMe)₂,

Fmoc-Gly-Gly-Phe-(OEt)₂,

Bz-Gly-Gly-Phe-(0/Pr)₂,

Bz-Gly-Gly-Phe-(0/Bu)₂,

Fmoc-Gly-Gly-Phe-(0/Pr)₂,

Fmoc-Gly-Gly-Phe-(0/Bu)₂,

Cbz-Arg-Val-Tyr-(OMe)₂,

Cbz-Arg-Val-Tyr-(OEt)₂,

Ac-Arg-Val-Tyr-(OMe)₂,

Ac-Arg-Val-Tyr-(OEt)₂,

Cbz-Arg-Val-Tyr-(0/Pr)₂,

Cbz-Arg-Val-Tyr-(0/Bu)₂,

Ac-Arg-Val-Tyr-(0/Pr)₂,

Ac-Arg-Val-Tyr-(0/Bu)₂, Bz-Arg-Val-Tyr-(OMe)₂,

Bz-Arg-Val-Tyr-(OEt)₂,

Fmoc-Arg-Val-Tyr-(OMe)₂,

Fmoc-Arg-Val-Tyr-(OEt)₂,

Bz-Arg-Val-Tyr-(0/Pr)₂,

Bz-Arg-Val-Tyr-(0/Bu)₂,

Fmoc-Arg-Val-Tyr-(0/Pr)₂,

Fmoc-Arg-Val-Tyr-(0 /Bu)₂,

Cbz-Feu-Val-Tyr-(OMe)₂,

Cbz-Feu-Val-Tyr-(OEt)₂,

Ac-Feu-Val-Tyr-(OMe)₂,

Ac-Feu-Val-Tyr-(OEt)₂,

Cbz-Eeu-Val-Tyr-(0/Pr)₂,

Cbz-Eeu-Val-Tyr-(0/Bu)₂,

Ac-Leu-Val-Tyr-(0/Pr)₂,

Ac-Eeu-Val-Tyr-(0/Bu)₂

Bz-Feu-Val-Tyr-(OMe)₂,

Bz-Feu-Val-Tyr-(OEt)₂,

Fmoc-Feu-Val-Tyr-(OMe)₂,

Fmoc-Feu-Val-Tyr-(OEt)₂,

Bz-Eeu-Val-Tyr-(0/Pr)₂,

Bz-Eeu-Val-Tyr-(0/Bu)₂,

Fmoc-Eeu-Val-Tyr-(0/Pr)₂,

Fmoc-Eeu-Val-Tyr-(0/Bu)₂,

Cbz-Ala-Val-Feu-(OMe)₂,

Cbz-Ala-Val-Feu-(OEt)₂,

Ac-Ala-Val-Feu-(OMe)₂,

Ac-Ala-Val-Feu-(OEt)₂,

Cbz-Ala-Val-Eeu-(0/Pr)₂,

Cbz-Ala-Val-Eeu-(0/Bu)₂,

Ac-Ala-Val-Eeu-(0/Pr)₂,

Ac-Ala-Val-Eeu-(0/Bu)₂,

Bz-Ala-Val-Feu-(OMe)₂,

Bz-Ala-Val-Feu-(OEt)₂,

Fmoc-Ala-Val-Feu-(OMe)₂,

Fmoc-Ala-Val-Feu-(OEt)₂,

Bz-Ala-Val-Eeu-(0/Pr)₂,

Bz-Ala-Val-Eeu-(0/Bu)₂,

Fmoc-Ala-Val-Eeu-(0/Pr)₂,

Fmoc-Ala-Val-Eeu-(0/Bu)₂,

Cbz-Arg-Ala-Feu-(OMe)₂,

Cbz-Arg-Ala-Feu-(OEt)₂,

Ac-Arg-Ala-Feu-(OMe)₂, Ac-Arg-Ala-Leu-(OEt)₂,

Cbz-Arg-Ala-Leu-(0/Pr)₂,

Cbz-Arg-Ala-Leu-(0/Bu)₂,

Ac-Arg-Ala-Leu-(0/Pr)₂,

Ac-Arg-Ala-Leu-(0/Bu)₂,

Bz-Arg-Ala-Leu-(OMe)₂,

Bz-Arg-Ala-Leu-(OEt)₂,

Fmoc-Arg-Ala-Leu-(OMe)₂,

Fmoc-Arg-Ala-Leu-(OEt)₂,

Bz-Arg-Ala-Leu-(0/Pr)₂,

Bz-Arg-Ala-Leu-(0/Bu)₂

Fmoc-Arg-Ala-Leu-(0/Pr)₂,

Fmoc-Arg-Ala-Leu-(0/Bu)₂,

Cbz-Arg-Val-Leu-(OMe)₂,

Cbz-Arg-Val-Leu-(OEt)₂,

Ac-Arg-Val-Leu-(OMe)₂,

Ac-Arg-Val-Leu-(OEt)₂,

Cbz-Arg-Val-Leu-(0/Pr)₂,

Cbz-Arg-Val-Leu-(0/Bu)₂,

Ac-Arg-Val-Leu-(0/Pr)₂,

Ac-Arg-Val-Leu-(0/Bu)₂,

Bz-Arg-Val-Leu-(OMe)₂,

Bz-Arg-Val-Leu-(OEt)₂,

Fmoc-Arg-Val-Leu-(OMe)₂,

Fmoc-Arg-Val-Leu-(OEt)₂,

Bz-Arg-Val-Leu-(0/Pr)₂,

Bz-Arg-Val-Leu-(0/Bu)₂,

Fmoc-Arg-Val-Leu-(0/Pr)₂,

Fmoc-Arg-Val-Leu-(0/Bu)₂,

Cbz-His-Ala-Tyr-(OMe)₂,

Cbz-His-Ala-Tyr-(OEt)₂,

Ac-His-Ala-Tyr-(OMe)₂,

Ac-His-Ala-Tyr-(OEt)₂,

Cbz-His-Ala-Tyr-(0/Pr)₂,

Cbz-His-Ala-Tyr-(0/Bu)₂,

Ac-His-Ala-Tyr-(0/Pr)₂,

Ac-His-Ala-Tyr-(0/Bu)₂,

Bz-His-Ala-Tyr-(OMe)₂,

Bz-His-Ala-Tyr-(OEt)₂,

Fmoc-His-Ala-Tyr-(OMe)₂,

Fmoc-His-Ala-Tyr-(OEt)₂,

Bz-His-Ala-Tyr-(0/Pr)₂,

Bz-His-Ala-Tyr-(0/Bu)₂,

Fmoc-His-Ala-Tyr-(0/Pr)₂, Fmoc-His-Ala-Tyr-(0/Bu)₂,

Cbz-His-Ala-Leu-(OMe)₂,

Cbz-His-Ala-Leu-(OEt)₂,

Ac-His-Ala-Leu-(OMe)₂,

Ac-His-Ala-Leu-(OEt)₂,

Cbz-His-Ala-Leu-(0/Pr)₂,

Cbz-His-Ala-Leu-(0/Bu)₂,

Ac-His-Ala-Leu-(0/Pr)₂,

Ac-His-Ala-Leu-(0/Bu)₂,

Bz-His-Ala-Leu-(OMe)₂,

Bz-His-Ala-Leu-(OEt)₂,

Fmoc-His-Ala-Leu-(OMe)₂,

Fmoc-Flis-Ala-Leu-(OEt)₂,

Bz-Flis-Ala-Leu-(0/Pr)₂,

Bz-Flis-Ala-Leu-(0/Bu)₂,

Fmoc-Flis-Ala-Leu-(0/Pr)₂,

Fmoc-Flis-Ala-Leu-(0/Bu)₂,

Cbz-lle-Pro-Tyr-(OMe)₂,

Cbz-lle-Pro-Tyr-(OEt)₂,

Ac-lle-Pro-Tyr-(OMe)₂,

Ac-lle-Pro-Tyr-(OEt)₂,

Cbz-lle-Pro-Tyr-(0/Pr)₂,

Cbz-lle-Pro-Tyr-(0/Bu)₂,

Ac-lle-Pro-Tyr-(0/Pr)₂,

Ac-lle-Pro-Tyr-(0/Bu)₂,

Bz-lle-Pro-Tyr-(OMe)₂,

Bz-lle-Pro-Tyr-(OEt)₂,

Fmoc-lle-Pro-Tyr-(OMe)₂,

Fmoc-lle-Pro-Tyr-(OEt)₂,

Bz-lle-Pro-Tyr-(0/Pr)₂,

Bz-lle-Pro-Tyr-(0/Bu)₂,

Fmoc-lle-Pro-Tyr-(0/Pr)₂,

Fmoc-lle-Pro-Tyr-(0/Bu)₂,

Cbz-lle-Gly-Phe-(OMe)₂,

Cbz-lle-Gly-Phe-(OEt)₂,

Ac-lle-Gly-Phe-(OMe)₂,

Ac-lle-Gly-Phe-(OEt)₂,

Cbz-lle-Gly-Phe-(0/Pr)₂,

Cbz-lle-Gly-Phe-(0 'Bu)₂,

Ac-lle-Gly-Phe-(0/Pr)₂,

Ac-lle-Gly-Phe-(0/Bu)₂,

Bz-lle-Gly-Phe-(OMe)₂,

Bz-lle-Gly-Phe-(OEt)₂, Fmoc-l le-Gly-Phe-(OMe)₂,

Fmoc-l le-Gly-Phe-(OEt)₂,

Bz-l le-Gly-Phe-(0/Pr)₂,

Bz-l le-Gly-Phe-(0/Bu)₂,

Fmoc-l le-Gly-Phe-(0/Pr)₂,

Fmoc-l le-Gly-Phe-(0/Bu)₂,

Cbz-Val-Ala-Norvaline-(OMe)₂,

Cbz-Val-Ala-Norvaline-(OEt)₂,

Ac-Val-Ala-Norvaline-(OMe)₂,

Ac-Val-Ala-Norvaline-(OEt)₂,

Cbz-Val-Ala-Norvaline-(0/Pr)₂,

Cbz-Val-Ala-Norvaline-(0/Bu)₂,

Ac-Val-Ala-Norvaline-(0/Pr)₂,

Ac-Val-Ala-Norvaline-(0/Bu)₂,

Bz-Val-Ala-Norvaline-(OMe)₂,

Bz-Val-Ala-Norvaline-(OEt)₂,

Fmoc-Val-Ala-Norvaline-(OMe)₂,

Fmoc-Val-Ala-Norvaline-(OEt)₂,

Bz-Val-Ala-Norvaline-(0/Pr)₂,

Bz-Val-Ala-Norvaline-(0/Bu)₂,

Fmoc-Val-Ala-Norvaline-(0/Pr)₂,

Fmoc-Val-Ala-Norvaline-(0/Bu)₂,

Cbz-Val-Ala-T rimethylsilyl-Ala-(OMe)₂, Cbz-Val-Ala-T ri methylsi ly I -Ala- (OEt)₂, Ac-Val-Ala-T rimethylsilyl-Ala-(OMe)₂, Ac-Val-Ala-T ri methylsi ly I -Ala-(OEt)₂, Cbz-Val-Ala-T rimethylsilyl-Ala-(0/Pr)₂, Cbz-Val-Ala-T rimethylsilyl-Ala-(0/Bu)₂, Ac-Val-Ala-T rimethylsilyl-Ala-(0/Pr)₂, Ac-Val-Ala-T rimethylsilyl-Ala-(0/Bu)₂, Bz-Val-Ala-T rimethylsilyl-Ala-(OMe)₂, Bz-Val-Ala-T ri methylsi ly I -Ala-(OEt)₂, Fmoc-Val-Ala-T rimethylsilyl-Ala-(OMe)₂, Fmoc-Val-Ala-T ri methylsi ly I -Ala- (OEt)₂, Bz-Val-Ala-T rimethylsilyl-Ala-(0/Pr)₂, Bz-Val-Ala-T rimethylsilyl-Ala-(0/Bu)₂, Fmoc-Val-Ala-T rimethylsilyl-Ala- (0 /P r) ₂, Fmoc-Val-Ala-T rimethylsilyl-Ala- (0 /Bu) ₂,

Cbz-Val-Ala-Cyclohexyl-Ala-(OMe)₂,

Cbz-Val-Ala-Cyclohexyl-Ala-(OEt)₂,

Ac-Val-Ala-Cyclohexyl-Ala-(OMe)₂,

Ac-Val-Ala-Cyclohexyl-Ala-(OEt)₂,

Cbz-Val-Ala-Cyclohexyl-Ala-(0/Pr)₂, Cbz-Val-Ala-Cyclohexyl-Ala-(0/Bu)₂,

Ac-Val-Ala-Cyclohexyl-Ala-(0/Pr)₂,

Ac-Val-Ala-Cyclohexyl-Ala-(0/Bu)₂,

Bz-Val-Ala-Cyclohexyl-Ala-(OMe)₂,

Bz-Val-Ala-Cyclohexyl-Ala-(OEt)₂,

Fmoc-Val-Ala-Cyclohexyl-Ala-(OMe)₂,

Fmoc-Val-Ala-Cyclohexyl-Ala-(OEt)₂,

Bz-Val-Ala-Cyclohexyl-Ala-(0/Pr)₂,

Bz-Val-Ala-Cyclohexyl-Ala-(0/Bu)₂,

Fmoc-Val-Ala-Cyclohexyl-Ala-(0/Pr)₂ and

Fmoc-Val-Ala-Cyclohexyl-Ala-(0/Bu)₂.

12. Use of the com pou nd according to any one of claims 1 to 11 for stabilizing an enzyme.

13. Use according to claim 12, wherein the enzyme is a hydrolase, preferably a protease.

14. A composition com prising a com pou nd according to any one of claims 1 to 11 and an enzyme, preferably a hyd rolase, more preferably a protease.

15. A com position according to claim 14, wherein the protease is a serine protease and preferably is a su btilisin protease.

16. The composition according to any one of claims 14 or 15, wherein the com position fur ther comprises a su rfactant.

17. The composition according to any one of claims 14 to 16, wherein the composition is in liquid or granu lar form.

18. The composition according to any one of claims 14 to 17, wherein the com position com prises at least a second enzyme different from the first enzyme, preferably a li pase, protease, cutinase, amylase, carbohydrase, cel lulase, pectinase, pectate lyase, man nanase, arabinase, galactanase, xylanase, oxidase, laccase or peroxidase.

19. A method of preparing the composition according to any one of claims 14 to 18 com prising the step of mixing the enzyme, preferably the hyd rolase, more preferably the protease, the com pou nd of formu la (I) of any one of claims 1 to 11.

20. Detergent com position com prising the com pou nd according to any one of claims 1 to 11 or the com position according to any one of claims 14 to 18 and optional ly a surfac tant.

21. A method of preparing a compou nd of formu la (I) com prising the steps:

O a) providing a com pou nd according to formu la

d) optionally, converting the compound obtained in step c) to

not hydrogen;

R 1

}H

e) reacting the compound obtained in step c) or d) with ^ZK O to obtain a

p4

O R² O' compound according to formula (I) ^H R ^{1 H} OfV R³

wherein X is selected from F, Cl, Br and I; and

wherein R¹ to R⁵ and Z are defined as in claim 1.